Evolutionary studies of metabolic networks on the basis of genome information

Tsuyoshi Tanaka

Doctor of Philosophy

Department of Genetics
School of Life Science
The Graduate University for Advanced Studies
2003 (School Year)

Acknowledgements

I wish to express my sincere gratitude to my supervisor, Professor Takashi Gojobori for his continuous guidance and encouragement during all the stages of this work. I thank Professors Yoshio Tateno, Toshimichi Ikemura, Naruya Saito, Fumiaki Yamao, and Associate Professor Yoko Satta for their useful comments on my work, serving as the members of my supervisory committee. I wish to express my appreciation to Associate Professor Kazuho Ikeo and Assistant Professor Yoshiyuki Suzuki for their valuable advices. I would appreciate the support and encouragement of all of my colleagues and friends at National Institute of Genetics. Finally, I would like to dedicate this thesis to my parents, Yasuo and Masako, and other family members, Kiyoko and Satoshi.

Contents

Acknowledgements

Contents

Abstract

| Chapter 1 Introduction | 1 |
|---|------------------------|
| 1.1 Complete genome sequence data | 1 |
| 1.2 Metabolic network as an example of biological network for the | ne evolutionary |
| study | 2 |
| 1.3 Evolutionary study of the metabolic networks in the viewpoir | nt of gain and loss of |
| genes | 4 |
| | |
| | |
| Chapter 2 Evolution of metabolic networks by | gain and loss of |
| Chapter 2 Evolution of metabolic networks by enzymatic reaction in eukaryotes | |
| - | 8 |
| enzymatic reaction in eukaryotes | 8 |
| enzymatic reaction in eukaryotes | |

| 2.3.3 Evolution of lipid and complex lipid metabolisms by gain of ERs in | the |
|--|-----------|
| vertebrate lineage | 18 |
| 2.4 Discussion | 20 |
| | B . 19 |
| Chapter 3 Evolution of Vitamin B ₆ (Pyridoxine) meta | ibolism |
| by gain and loss of genes | 38 |
| 3.1 Introduction | 38 |
| 3.2 Materials and methods | 41 |
| 3.2.1 Genes related to the VB6 metabolism | 41 |
| 3.2.2 Phylogenetic tree | 42 |
| 3.2.3 Estimation of the gene set of the VB6 metabolism in the ancestor | 42 |
| 3.2.4 The order of the losses among the genes | 43 |
| 3.3 Results | 44 |
| 3.3.1 Comparison of the gene sets among species | 44 |
| 3.3.2 Distribution of the genes in the three domains of life | 44 |
| 3.3.3 Estimation of the losses of genes | 45 |
| 3.3.4 Losses of SNO and SNZ in animal lineages | 46 |
| 3.3.5 Correlation of losses of genes among PLP biosynthetic pathways | 47 |
| 3.4 Discussion. | 48 |
| | 40 |
| Chapter 4 Conclusion | 08 |
| References | 70 |

Supplementary table 1

Supplementary table2

Supplementary results1

Supplementary results2

Abstract

A variety of biological molecules play important roles in maintaining life through their intermingling networks. The metabolic network is one of them that function as the interactions between substrates and enzymes. In other words, the metabolic network is composed of the enzymatic reactions (ERs) in which one or more than one enzymes catalyze the reaction of the pertinent substrates. Since the metabolism is a basal system for maintaining life of all organisms, any changes of the metabolic networks must have greatly affected the organismic evolution. In this thesis, I have studied the evolution of the metabolic networks using the complete genome sequences and genealogical relationships among species. Based on the complete gene sets of the species studied, I examined whether a particular enzyme encoded by its gene existed in In particular, I conducted a comparative analysis of the the species of interest. metabolic networks among the species using the set of genes. First, I investigated the evolutionary process of the metabolic networks focusing on the gain and loss of ERs, because a single gene often functioned in more than one ER in the metabolic networks. Next, taking the pathways of vitamin B₆ (VB6) metabolism as an example, I systematically estimated the gain and loss of the genes during evolution of the species in order to elucidate the evolutionary process of the metabolic networks. examination, I used genes instead of ERs because I was able to identify directly the genes encoding for particular enzymes that were involved with the corresponding ERs in the pathways of VB6 metabolism.

In Chapter 1, I have given an overview of my evolutionary study of the metabolic

networks using the complete genome sequences. Here, I have also described the motivation and purposes of the present study.

In Chapter 2, I conducted comparative studies of ERs in the metabolic networks among the 6 eukaryotic species whose complete genome sequences were determined. For prokaryotes, it has been known that many gene losses had occurred during evolution. For eukaryotes, however, the evolutionary events of the gain and loss of genes in the metabolic networks are unknown, because no systematic studies have been conducted so far. The aim of this chapter is to examine how often gains and losses of enzymatic reactions (ERs) have occurred during the evolution of metabolic networks in eukaryotes, and how these evolutionary events have affected phenotypic traits of the As a result, I found that the losses of ERs had occurred more frequently organisms. than the gains during the evolutionary diversification of metabolic networks in different lineages of eukaryotic species. However, the vertebrate lineage after the separation from Drosophila melanogaster showed a remarkable increase in the number of ER gains compared with that of ER losses. In particular, 41% of ER gains were deeply involved with the lipid and complex lipid metabolisms. Because some products of these two metabolisms function as hormones, I concluded that ER gains of the two metabolisms accelerated the development of hormonal signal transduction for the elaborated regulation of physiological system during the vertebrate evolution.

In Chapter 3, in order to understand the evolutionary process of the metabolic networks in more details, I focused upon the VB6 metabolism as an example. The group of VB6, particularly pyridoxal 5'-phosphate (PLP), functions as a cofactor of diverse enzymes in the amino acid metabolisms. Most unicellular organisms and plants can biosynthesize PLP using any one of the three known PLP biosynthetic

pathways; the *de novo* pathway, the salvage pathway and the fungi-type pathway. On the other hand, animals such as insects and mammals have to take it as nourishment because there is a deficiency in the VB6 metabolism in animal lineages. To understand the evolutionary diversification and breakdown of the VB6 metabolism from the viewpoint of gain and loss of the genes, I conducted a comparative analysis of the sets of the genes involved in the VB6 metabolism among the 122 species, including prokaryotes, whose genome sequences were completely determined. In this study, I discussed directly the gain and loss of genes instead of ERs. As a result, I found that any of 10 genes examined was lost more than once in the evolutionary lineages of the 122 species examined. I have also made the following three findings in the evolution of VB6 biosynthesis: (1) A breakdown of the fungi-type pathway occurred at least three times independently in some of animal lineages, (2) the de novo pathway was established by generation of the pdxB gene in gamma-proteobacteria, and (3) a particular order of gene losses in the PLP biosynthetic pathways was evolutionarily conserved among lineages of the different species. These findings strongly suggest that an evolutionary process of the vitamin B₆ metabolism had been quite dynamic through the events of gain and loss of the genes during evolution of the 122 species examined.

Finally, in Chapter 4, I described the conclusions of the present studies. In particular, I have come to the conclusion that the study of the gain and loss of ERs provides us with profound insight into the understanding of the evolutionary process of metabolic networks. Moreover, I have concluded that the gain and loss of ERs not only played important roles in evolutionary diversification of the metabolic networks, but also greatly affected the whole evolutionary process from prokaryotes to eukaryotes.

Chapter 1

Introduction

1.1 Complete genome sequence data

Since the complete genome sequence of *Haemophilus influenzae Rd* was obtained in 1995 (Fleischmann *et al.* 1995), the available number of the completely sequenced genomes has been still increasing. As of November in 2003, we have 150 species whose compete genome sequences are stored in the Genome Information Broker (GIB), the database collecting the complete genome sequences at DDBJ/NIG (the DNA Data Bank of Japan at National Institute of Genetics) (Fumoto *et al.* 2002). The contents of the 150 species are 128 eubacteria, 16 archaebacteria and 6 eukaryotes. Using the complete genome sequence data, we can conduct a comparative study of the genome sequences among the different species in order to know the existence or the absence of particular genes in the species of interest (Huynen *et al.* 1999). Conducting the large-scale comparative analysis of the complete genome sequence data, I studied the evolutionary process of the metabolic networks from the viewpoint of gains and losses of the genes.

1.2 Metabolic network as an example of biological network for the evolutionary study

I am very much interested in the evolution of the biological networks. In particular, as I mentioned in the previous section, the complete genome sequences provided me with a unique opportunity for conducting the evolutionary study of biological networks because the dataset of all possible proteins encoded by the genes becomes available for large-scale comparisons.

Table 1-1 shows the types of the biological networks which are composed by the interactions between the protein and the other molecules. In the network of the transcriptional regulation, for example, the interaction between the protein called a transcriptional factor and the DNA segment called a regulatory region is mainly needed for transcriptional regulation (Lee *et al.* 2002). In the metabolic network, as another example, low-molecular chemical compounds called "substrates" and proteins called "enzymes" interact with each other (Schuster *et al.* 2000).

In my study, I decided to take the metabolic networks as a typical example of biological network in order to understand their evolutionary process. This is mainly because the metabolic networks have been well studied, so that enzymatic reactions (ERs) can be relatively easily identified by the gene prediction conducted on the complete genome sequence data. The metabolic network is also called the metabolic pathway. In this thesis, I use the term "network" in which various molecules just interact with each other and I ignore direction of the ERs in which the certain substrate is converted to the product by the particular enzyme. On the other hand, when I consider the direction of the interaction, I call that network as a "pathway".

The comparison of metabolic networks among different species has also suggested that both gains and losses of the genes encoding enzymes have often occurred in prokaryotes during evolution (Tatusov *et al.* 1996). For eukaryotes, however, there is no systematic study of evolutionary events of the gain and loss of genes in the metabolic networks. Thus, the following questions are immediately raised: How have the metabolic networks evolved in eukaryotes? To answer this important question, we have to detect, first, the evolutionary changes in the metabolic networks from the viewpoint of gains and losses of ERs.

1.3 Evolutionary study of the metabolic networks in the viewpoint of gains and losses of genes

The metabolism is the basal system to maintain the life from the unicellular organisms to the multicellular organisms. The evolution of the metabolic networks must have affected greatly the life system of the species. Because of this nature, the metabolic networks are thought to be evolutionarily conserved among the species. However, it has been known that there are differences in the metabolic networks among the species, and therefore it is of particular interest to conduct the comparison of the metabolic networks between different species of organisms (Bono *et al.* 1998; Peregrin-Alvarez *et al.* 2003). For conducting this line of study, I would also note that there are various databases which are useful and available freely (Table 1-2).

Taking these advantages of studying the metabolic networks, I conducted comparative analyses of the metabolic networks between different species on the basis of the genome sequence information. The most characteristic point of the present study is to examine the genomic changes of the metabolic networks by estimating the gain or loss of genes and enzymatic reactions (ERs). In particular, I estimated the events of gains or losses of genes and ERs in evolutionary lineages of the species by combining the genomic information with the genealogical relationships among the species. Based upon these results, I discussed the evolutionary process of the metabolic networks in the following chapters.

In this thesis, I utilized the two databases, KEGG and ExPASy database. I could gather the dataset of the entire gene sets from the prokaryotes to eukaryotes are included in the KEGG databases. Moreover, by connecting the KEGG and ExPASy databases, I

When I evaluated the effect of the gain and loss of genes and ERs against the phenotypic traits of the species examined, the categorized 104 metabolic networks in KEGG database could be useful. The other three databases also have the numerous dataset of the metabolic networks, however, I could not utilize them. In the case of BioCyc, the dataset concerned with *E. coli* was massive, however, the dataset of eukaryotes was less enough than that of KEGG and ExPASy. The dataset of the function of the gene in the UM-BBD database is linked to the KEGG database. Therefore, I did not need to the UM-BBD database for the function of the gene. Even though the WIT database contains the original set of the orthologous genes mainly for the bacteria, total number of species in the WIT is less than that of KEGG and ExPASy. Therefore, I also did not use this database instead of the KEGG and ExPASy database.

| Table 1-1. Networks in the living organism | |
|--|----------------------------|
| Component (The type of interaction) | Example of major network |
| Protein - DNA | Transcriptional regulation |
| Protein – RNA | Translation |
| Protein - Protein | Signal transduction |
| Protein - Low-molecular compound | Metabolic network |
| | Signal transduction |

Table 1-2. Database related to the metabolism

| Database | URL | Ref. |
|----------|-------------------------------|-------------------------|
| KEGG | http://www.genome.ad.jp/kegg/ | (Kanehisa et al. 2002) |
| ExPASy | http://kr.expasy.org/ | (Gasteiger et al. 2003) |
| BioCyc | http://biocyc.org/ | (Karp et al. 2002) |
| UM-BBD | http://umbbd.ahc.umn.edu/ | (Ellis et al. 2003) |
| WIT | http://wit.mcs.anl.gov/WIT2/ | (Overbeek et al. 2000) |

Chapter 2

Evolution of metabolic networks by gain and loss of enzymatic reaction in eukaryotes

2.1 Introduction

Metabolisms of the living system are complex networks of physico-chemical processes, most of which are catalyzed by enzymes. The complete genome sequences allow us to obtain the comprehensive data set of genes encoding enzymes in the metabolic networks (Tweeddale et al. 1998; Covert et al. 2001). Moreover, even if experimental studies have not been conducted in a species, it has become possible that we reconstruct the metabolic networks on the basis of the prediction of the gene and its function from the complete genome sequence data (Gaasterland and Selkov 1995). Using these approaches, the comparative studies of metabolic networks have been conducted in prokaryotes (Huynen et al. 1999; Forst and Schulten 2001). studies suggest that for the prokaryotic species, both the gain and loss of genes have often occurred during the evolution of metabolic networks (Tatusov et al. 1996). In particular, the loss of genes has frequently occurred in parasitic and symbiotic bacteria (Shigenobu et al. 2000; Akman et al. 2002; Oshima et al. 2003). Although models have been proposed to explain the evolutionary mechanism of metabolic networks by the gain of enzymes (Horowitz 1945; Jensen 1976; Schmidt et al. 2003), the comparative studies of bacterial genomes have shown that it is not sufficient to consider only the gain of genes for explaining the evolution of metabolic networks in the

prokaryotic lineage (Himmelreich et al. 1996; Cole et al. 2001).

In the case of eukaryotes, there are a few reports that the loss of genes might have occurred in the metabolic pathway such as a vitamin biosynthetic pathway (Smirnoff 2001). However, there is no systematic study of evolutionary events of the gain and loss of ER in the metabolic networks of eukaryotes, particularly in multicellular organisms. Thus, the following questions are immediately raised to understand the evolutionary process of the metabolic networks in eukaryotes: How have the metabolic networks evolved and how were they diversified during the evolution of the three kingdoms of eukaryotes? Moreover, it is also a question of interest to ask how the diversification of the metabolic networks affected phenotypic traits of organisms.

To answer the above-mentioned questions, I conducted comparative studies of the metabolic networks among 6 eukaryotic species whose genome sequences were completely determined. Using the gene set predicted from the complete genome sequence, I examined whether a particular gene does exist or not in the species.

In this study, I made the following assumptions. First, I consider that a metabolic network in a species is composed of a set of ERs, and I used this set of ERs to compare the metabolic networks among the 6 species. Because a single gene may be involved with more than one ER, my attention has been paid to ERs rather than enzymes or genes themselves in this study. Second, if the two genes encoded the homologous protein sequences, they are assumed to share the same gene function that is represented by a single ER. Thus, I conducted the comparative studies of the ER set in metabolic networks between different species, on the basis of the prediction of gene function through the sequence homology. Finally, I assumed that for a given metabolic network, all the sets of ERs for the 6 eukaryotic species must have been derived from

the single common ancestor (Lazcano and Miller 1999). In other words, I ignored the effect of any possible horizontal gene transfer and parallel evolution against the result of this study. In the case of the horizontal gene transfer, it was mainly reported in prokaryotes (Lawrence JG. 2002), and in eukaryotes, especially H. sapiens, the estimated number of horizontal transferred genes is small (Salzberg et al. 2001). Therefore, I considered that the gain of ER by horizontal gene transfer had occurred rarely in the eukaryotic lineage. On the other hand, the parallel evolution did not affect to the result of this study, because independent generations of homologous sequences between different species are considered to occur rarely. From these reasons, I considered that the effects of those kinds of evolutionary events can be very small in the present analysis. Therefore, I considered that same ERs shared by the species generated by only one evolutionary event during the evolution of the metabolic networks when I estimated the ERs based on the sequence homology. estimated the ancestral ER set from the comparison of the 6 extant species on the basis of genealogical relationship. Then, I identified the gain and loss events of ERs from the comparison of the ER sets between the ancestral and extant species.

My comparative studies have shown drastic differences of metabolic networks among the species examined. I have also attempted to make answers to the question which lineage has had the change of metabolic networks during evolution, from the viewpoint of the relationship between the differentiation of the metabolic networks and phenotypic traits of organisms. Thus, this study would give us an important clue in understanding the evolutionary processes of the metabolic networks in each lineage.

2.2 Materials and Methods

2.2.1 Database and species-ER matrix

The present analysis of metabolic networks based on sequence information of enzymes requires the access to adequate databases. Kyoto Encyclopedia of Genes and Genomes (KEGG) provides both an online map of metabolic networks and the annotation of enzymatic reactions for species of interest (Kanehisa et al. 2002). In the KEGG database, the function prediction for an enzyme encoded by a gene was updated daily by both computational and manual approaches using sequential and experimental evidence. For identifying the set of ERs for a given metabolic network, I used a total of 94,000 protein sequences reported, in the KEGG database, for the 6 eukaryotic species (Homo sapiens, Drosophila melanogaster, Caenorhabdits elegans, Saccharomyces cerevisiase, Schizosaccharomyces pombe, and Arabidopsis thaliana) whose complete geneome sequences have been determined, as of 20th April 2003. Although the 94,000 protein sequences contain gene products for both metabolic and non-metabolic enzymes, curation is relatively well-conducted for a larger part of genes encoding metabolic enzymes in these protein sequences of the KEGG database.

Expert Protein Analysis System (ExPASy) proteomics server of the Swiss Institute of Bioinformatics (SIB) also provides the database of the functional categorization and its relevant literature of enzymes as well as analytical tools dedicated to the study of proteomics (Gasteiger *et al.* 2003). For identifying ERs in the metabolic networks from protein sequence families, I also used the ExPASy databases in order to ensure the validity of functional identification of ERs. This is because a metabolic network in a species is assumed to be composed of a set of ERs that is used

for making comparison of the metabolic networks among different species.

For making the homologous protein sequence families on the basis of the predicted genes in the complete genome sequence data, I used the blastp homology search (Altschul *et al.* 1990).

First, I classified 94,000 protein sequences into the homologous sequence families, setting up the threshold of E-value to be 10⁻⁵. Because the homologous sequence families, of course, depend on the threshold of E-value, I examined four different E-values for the threshold: 10⁻¹⁰⁰, 10⁻⁵⁰, 10⁻¹⁰, and 10⁻⁵. When I took 10⁻¹⁰⁰ and 10⁻⁵⁰, the number of sequences in one sequence family became so small that identification of ERs was virtually impossible. On the other hand, whichever 10⁻¹⁰ or 10⁻⁵ is taken, the numbers of sequences in the family were almost the same. Because 10⁻⁵ is often used for homology search for gene prediction in the genome studies (Read *et al.* 2003; Galagan *et al.* 2003), I took 10⁻⁵ as the threshold of E-value in the present study. As mentioned above, I identified a total of 751 ERs in 104 different kinds of metabolic networks based on the KEGG and ExPASy databases, obtaining 751 corresponding protein families from the homology search of predicted gene sequences in the complete genomes.

Second, in order to know how many ERs a given species possesses in its relevant metabolic networks, I examined whether each of the 751 ERs existed in the metabolic networks of a species of interest. In practice, if a species has a particular protein sequence that is contained in the family corresponding to an ER, I decided that the species had the ER.

Third, I created a dataset of ERs for the out-group species of eukaryotes, because I had to estimate an ER set of the ancestral species using the out-group species (See the

next section). As the dataset of ERs in the out-group species, I used the dataset of bacterial ERs that was included in the "enzyme" dataset provided by the KEGG database. In practice, I constructed the dataset of the out-group ER set that was made by taking a union of all ER sets among all the 112 bacterial species examined because I did not deal with the gain and loss of ERs in the bacterial lineage in this study.

Fourth, for the ER sets of the 6 eukaryotic species together with the out-group ER set, I formed a matrix of 7 x 751 whose element was n_{ij} (i = 1,2,..., and 7, and j = 1,2,..., and 751), where n_{ij} is represented by the following two states: $n_{ij} = 1$ when the i-th species had at least one gene for the j-th ER, and $n_{ij} = 0$ when the i-th species had no gene for the j-th ER. Let us call this matrix as the ER matrix. Thus, the ER matrix was used for the comparison of the set of ERs among species.

2.2.2 Estimation of an ER set comprising metabolic networks in the ancestor

I used a phylogenetic tree that was based on the study of Baldauf *et al.* (2000) to estimate the ER sets of the ancestor of the eukaryotes. For estimating the ancestral set of ERs, I used the ER matrix comparing the 0-1 state elements as mentioned above. There are five internal-nodes in the phylogenetic tree of the 6 eukaryotes. As the first step, I estimated the state (0 or 1) at the immediately common ancestral node of the neighboring two species in the tree by comparing between the states of the two species (Figure 2-1). If two states were the same, namely (0,0) or (1,1), I assumed that the ancestor has the same state, meaning that nothing had changed (Patterns 1 and 2 in Figure 2-1). If two states were different, namely (0,1) or (1,0), I examined the states for all of species that were located in the outside of the two comparing species in the

tree and out-group species. Let me denote a group of those species by species group C. If at least one species in group C have the state of "1", I estimated the ancestral state to be "1" (Pattern 3 in Figure 2-1). If all species of group C have the state of "0", I estimated the ancestral state to be "0" (Pattern 4 in Figure 2-1). In this way, I estimated the states at all internal-nodes for a given ER. Thus, for a given species or ancestral node, the number of existing ERs has been easily obtained by the sum of all the states (0 or 1) over all possible ERs. Thus, the number of existing ERs can be compared between different species. Note that my estimations are based upon the assumption that a single ER was acquired only once during evolution of the 6 eukaryotes in this model. As a result, the number of ERs composing the metabolic networks in the common ancestor of all the 6 eukaryotes was 622.

A total of 104 kinds of metabolic networks were classified into 11 categories according to the definitions given in the KEGG database. For a given category, I estimated how many ERs exist for each of all the 6 species.

2.3 Results

2.3.1 Comparison of the ER sets between different species

As shown in Table 2-1, the number of ERs varied considerably with species. In fact, the number of ERs was 417 in *S. pombe* at the smallest, and 578 in *H. sapiens* at the largest among the 6 species examined. When I counted the number of ERs that were commonly shared among all the 6 species, it was only 226, being 36% of the estimated 622 ERs of the common ancestor of the 6 eukaryotes. Thus, I found that the ERs must have undergone dynamic changes in the number of ERs during the evolutionary diversification of eukaryotic species.

When I compared the number of ERs for each of the 6 eukaryotes with that of the common ancestor of the 6 eukaryotes, I made a surprisingly interesting observation that the ancestor had the number of ERs larger than any of all the species examined. This result strongly suggests that the number of ERs decreased in the metabolic networks for all the lineages during evolution, implying that the losses of ERs occurred more frequently than the gains for all evolutionary lineages. Thus, this feature appears to be common between prokaryotes and eukaryotes.

When I focused on the gain and loss of ERs in each evolutionary lineage towards the extant species from the common ancestors, the total number of gains and losses of ERs varied considerably with evolutionary lineages; from 114 in *A. thaliana* at the smallest to 302 in *D. melanogaster* at the largest (Table 2-1). Interestingly, I observed that the number of losses of ER was more than the number of gains of ER in any of all evolutionary lineages examined. This reinforces my observation that the losses of ER occurred more frequently during the evolution of metabolic networks than the gains of

ER among the 6 eukaryotic species.

Next, I studied the distribution of ERs for the 104 different kinds of metabolic networks in the 6 eukaryotic species as well as the common ancestor of the 6 species (Table 2-2). In the 104 metabolic networks, there are only three networks that were not changed at all during evolution from the common ancestor to all the 6 extant species; the metabolic networks of ATP synthesis, 1,2-Dichloroethane degradation, and phospholipid degradation. It suggests that most of the metabolic networks had experienced one or more than one changes of gains or losses in the number of ERs in evolutionary lineages. It again indicates a dynamic feature of evolutionary changes in metabolic networks.

Interestingly enough, there are metabolic networks in which species-specific changes in the number of ERs were observed. For example, in the networks of valine-leucine-isoleucine biosynthesis, lysine biosynthesis and phenylalanine-tyrosine-tryptophan biosynthesis, the numbers of ERs were observed to have changed drastically only in the animal lineages of *H. sapiens*, *D. melanogaster* and *C. elegans*. For these three biosynthesis pathways, on the other hand, few changes were observed in the plant or yeast lineages of *A. thaliana*, *S. cerevisiae* and *S. pombe*. Moreover, it is of particular interest to note that the pathway of flavonoids, stilbene and lignin biosynthesis showed substantial increase in the number of ERs only in the plant lineage of *A. thaliana*. Because flavonoids are essential for plant reproduction (Winkel-Shirley 2002), the gains of ERs could have contributed to the establishment of the plant-specific system of the reproduction. Thus, such kinds of metabolic networks may have played an important role in characterization of species during evolutionary diversification.

My observation in which the number of ERs involved with the amino acid biosynthesis decrease in the animal lineage is supported by the fact that most species of plants and yeasts are known to be capable of biosynthesizing the amino acids whereas the animals such as human are required to obtain the so-called essential amino acids that are not produced by themselves.

2.3.2 The numbers of gains and losses of ERs

As mentioned above, the distribution of the number of ERs over the 104 metabolic networks were species-dependent as long as the 6 eukaryotes examined were This is also a strong indication that gains and losses, had taken place considerably in each lineage of the 6 species during evolution. When I analyzed the difference of the metabolic networks between the 6 eukaryotes based on the existence of ERs in detail, I discovered the metabolic networks of which I explained the difference between species by the following four patterns, conservation, alternative conservation, ER losses and ER gains, even if it was hard to categorize almost metabolic networks into each pattern (See the supplementary results1). When I counted the numbers of losses and gains separately, I found that a total numbers of 675 losses and 129 gains of ERs occurred in metabolic networks during evolution of the 6 eukaryotic species (Figure 2-2). It follows that 1.1 losses and 0.2 gains per ER, on the average, had occurred since the 622 ERs of the common ancestor diverged out to the 6 extant eukaryotes. Thus, the event of losses had occurred approximately five times more often than that of gains. Moreover, I found that 37% of 525 ERs, namely 193 ERs, had more than one loss or both of gain and loss of ERs in all the evolutionary lineages of the 6 species (Figure 2-3). It suggests that about one forth of ERs underwent several gains

or losses independently during the evolution of metabolic networks.

According to the KEGG database, the metabolic networks examined in the present study were separated into 11 different categories of biological function (Table 2-3). As shown in Table 2-3, it is interesting to see that the numbers of ER losses were larger than the numbers of ER gains in any of all categories. However, the differences in the numbers between ER losses and ER gains were very large, depending upon categories. I would point out that for the amino acid metabolism, both numbers of ER losses and gains were larger than those for the other categories. It indicates that ERs in the amino acid metabolism are quite flexible in the evolutionary change, probably because necessary amino acids can be acquired from the foods or symbiotic bacteria. On the other hand, in the metabolisms of complex carbohydrates and complex lipid, the numbers of ER gains were larger, compared with those of the other categories. This will be discusses later. These results strongly suggest that the likelihood of occurrences of the gains and losses of ERs depends upon metabolic category.

2.3.3 Evolution of lipid and complex lipid metabolisms by gain of ERs in the vertebrate lineage

I found that the evolutionary lineage toward the vertebrate showed the largest number of gains among the 6 species. In fact, this lineage had undergone 107 gains of ERs, which corresponds to 83% of the estimated number of ER gains. This is an amazingly large number of gains. More interestingly, I found that 46 out of 107 gains of ERs occurred in the lipid and complex lipid metabolisms, which corresponds to 43% of the total number of gains (Table 2-4). In particular, in the two metabolisms, a total of 17 ER gains out of 46 had occurred in the vertebrate lineage after the divergence

from *D. melanogaster*. Because only one ER loss had occurred in the same lineage, the number of ER gains is outstandingly high.

There are several explanations to be considered for the extraordinary gains of ERs in the vertebrate lineage. However, the most possible explanation is that the ER gains in the lipid and complex lipid metabolisms must have contributed to the evolutionary formation of an exquisite system of signal transduction in the vertebrate. This explanation is actually supported by the fact that the products of the two metabolisms were often involved deeply with the regulation system of signal transduction (Yamashita et al. 1999; Unger and Orci 2002; Kolesnick and Fuks 2003). In particular, the products of three metabolic networks such as the prostaglandin and leukotriene metabolism, the C21-steroid hormone metabolism and the androgen and estrogen metabolism, were known to work as hormones or autacoids in vertebrates (Huber and Gruber 2001; Funk 2001; Dubey et al. 2002). Hormones and autacoids are functionally very important for maintenance of the complex system of physiological regulations (Yamashita et al. 1999). When I looked at the prostaglandin and leukotriene metabolism, 6 gains of ERs were observed to have occurred in the vertebrate lineage. More interestingly 5 ERs out of 6 had emerged in the vertebrate lineage after the divergence between D. melanogaster and H. sapiens (Figure 2-4). The products derived from the gains of these ERs were all hormones that work in various physiological regulations such as the cell proliferation and constriction of sooth muscle (Table 2-5). These results suggest that the ER gains of the lipid and complex lipid metabolisms had played an important role in the evolution of the vertebrates whose system of physiological regulation is exquisitely complex.

2.4 Discussion

I examined the gain and loss of ERs in the metabolic networks for evaluating their evolutionary process. It is clear that the number of ERs examined is not enough to construct the complete metabolic networks in the 6 eukaryotes because the complete set of ERs for the metabolic networks has not been determined. There are so many ERs that have not been discovered yet. Therefore, it is hard to I conclude the correctness of the number of ERs in the ancestor and the absolute values of gain and loss of ERs. In other words, ascertain bias must exist in this study because the depth of the study for the metabolic networks is different between examined species. means that the number of gain of ERs will increases in any lineages because of the progress of the study of the novel ERs. However, number of ER gains is not larger than that of lost ERs in any lineage. This result suggests that a total number of ER gains will not be larger than that of lost ERs in this study even if the novel ERs are found. In fact, when I conducted the comparative analysis of the metabolic networks by the use of the set of 1,046 ERs, the number of gain of ERs increased in any lineage. However, the loss of ERs have occurred more frequently than the gain of them (Figure 2-5).

The ascertain bias was affected by the dataset of sequences that I used. In this study, I used the protein sequences of only 6 eukaryotes whose genome sequences were completely determined and I estimated the gain of ERs based on the distribution of homologous sequences involved with the ERs. However, if there are homologous sequences in other species that I did not use in this study, the time of the gain of ER must be changed. I evaluated the possibility by conducting the homology search of the

58 protein sequences discovered in only one species examined to the non redundant protein database as of Jan. 7th 2004. When I made the 58 phylogenetic trees using the matched sequences, there were 6 (10%) trees that the timing of ER gains may be doubtful in my estimation (See the supplementary results2). This result suggests that the timing of ER gain may be changeable by the increase of the sequences examined.

Moreover, In this study, the estimation of the gain and loss of genes was conducted with special care of the following two points; horizontal gene transfer and parallel evolution. Although I understand that these are important in the understanding of evolutionary mechanisms, I consider that they should not affect seriously the estimation of ER gains and losses in this study because of the reasons that I mentioned in the section of the introduction in this chapter. My results may be affected by a topology of the phylogenetic tree used. When I used two different topologies particularly regarding a plant and yeasts, the number of ERs of the common ancestor of the 6 eukaryotes and the numbers of the gains and losses of ERs were changed in some lineages (Figure 2-5). Because those changes are not substantial, however, the essential points of the results obtained remain unchanged.

In this study, I found that a lot of losses and gains of ERs had occurred during evolution of the 6 eukaryotic species whose complete genomes have been sequenced. In particular, the number of ERs in the extant 6 species varied considerably with the species. I fully understand that the estimated number of ERs may not be accurate. In particular, because the ERs were identified by the gene sequence families that were classified by homology search, I may have underestimated the number of ERs. However, although I may have missed other ERs that were not identified in the present study, it should not affect much the comparisons of ERs between different species.

This is because the same criteria of identifying ERs were always adopted equally to all the 6 eukaryotic species. From the same reasons, I must take with caution that the common ancestor of the 6 eukaryotic species must have had 622 ERs. This number of the ancestral ERs can be underestimated. However, I am not much interested in the absolute number of ERs, but am interested in the numbers of gains and losses of ERs in the evolutionary lineages from the common ancestor to each of the 6 species, as long as the ERs identified here are concerned. Thus, the present comparative study of ER gains and losses in the metabolic network should be valid. It is interesting to note that a total of 804 events of gains and losses were observed in the evolution of the ancestral 622 ERs. These tremendous evolutionary changes were, for the first time, found in the eukaryotic species by the comparative genome approach.

It is reasonable to consider that losses of ERs might affect the metabolic networks more seriously than gains of ERs, because even a single event of loss of ER possibly causes destruction of the metabolic network. Thus, it is quite possible that such losses of ERs would be selected against by severe pressures of negative selection. It is natural that the previous studies of metabolic networks have concentrated mostly on gains of ERs. In the present study, I found that the losses of ERs had occurred much more frequently than the gains of ERs in the eukaryotic species examined: The former occurred about five times frequently than the latter. This may be explained by heterotrophy in which the essential compounds for sustaining the life can be acquired from the other organisms. It is well exemplified by the amino acid metabolism. In this study, I found that a total of 156 ER losses in the amino acid metabolism and that most of those occurred in the animal lineages. It has been well known that for animals, the essential amino acids are obtained from the foods or symbiotic/parasitic bacteria

(Reeds and Garlick 2003), though most plants are completely autotrophic. Moreover, the metabolisms of carbohydrates and cofactors/vitamins had undergone more numbers of ER losses than the other metabolisms except the amino acid metabolism; 74 and 64 losses of ERs are observed, respectively. More than half of losses for both metabolisms occurred particularly in the animal lineages. These observations are also consistent with the well known facts that the animals usually need these essential compounds of nourishment from the environments. It is also possible that the lost ER can be complemented by another ER in the metabolic pathway. Thus, the result in the study is consistent with Jeong and his colleagues' speculation that the metabolic networks are robust, error-tolerant and scale-free (Jeong at al. 2000).

The ER gain is often used for explaining the evolution of the metabolic networks (Horowitz 1945; Jensen 1976; Schmidt *et al.* 2003). It is easily conceivable that the species gaining the new ER may become able to use a new substrate, leading to formation of the new system. In this study, I found that over one third of total ER gains concentrated on the lipid and complex lipid metabolisms in the vertebrate lineages from the common ancestor. Moreover, after the divergence from *D. melanogaster*, the vertebrate lineage had a total of 17 ER gains, though only one loss of ER had occurred in these categories of metabolic networks. Because some of the fat-soluble hormonal compounds were produced through the lipid and complex lipid metabolisms (Liston and Roberts 1985; Wen *et al.* 2003; Soberman and Christmas 2003), the ER gains of the lipid and complex lipid metabolisms enabled the species to develop the advanced hormonal system. It eventually led the species to the completion of the complex system of physiological regulation during the evolution in the vertebrate lineage.

In conclusion, I successfully estimated the gains or the losses of ERs, which

should give us important insight into the understanding of the evolutionary process of the metabolic networks.

Table 2-1. List of species

| Symbol | Name | ERs | Gain* | Loss* | Total |
|--------|--------------------------------|-----|-------|-------|-------|
| ATH | Arabidopsis thaliana | 538 | 15 | 99 | 114 |
| CEL | Caenorhabditis elegans | 465 | 52 | 209 | 261 |
| DME | Drosophila melanogaster | 454 | 67 | 235 | 302 |
| HSA | Homo sapiens | 578 | 107 | 151 | 258 |
| SCE | Saccharomyces cerevisiae S288C | 424 | 23 | 221 | 244 |
| SPO | Schizosaccharomyces pombe | 417 | 20 | 225 | 245 |

^{*}Number of the gain and loss was a total of counts from the common ancestor of the 6 eukaryotes to each extant species.

Table 2-2. Number of ERs in each metabolic networks in the 6 eukaryotes

| | N1CPD | | | | | | |
|---|---|------|-----|-----|-------|-----|----------|
| Matabalia naturada | Number of ER ANC H SA DME CEL SCE SPO A | | | | ACTIT | | |
| Metabolic network | ANC | H SA | DME | CEL | SCE | SPO | ATH |
| Amino Acid Metabolism | 22 | 21 | 1.4 | 12 | 10 | 20 | 22 |
| Urea cycle and metabolism of amino groups | 23 | | 14 | | | | |
| Glutamate metabolism | 26 | | 22 | 23 | | | 20 |
| Alanine and aspartate metabolism | 19 | | 17 | | | | 16 |
| Glycine, serine and threonine metabolism | 37 | | 24 | 22 | | | 24 |
| Methionine metabolism | 15 | | 8 | 8 | | | 9 |
| Cysteine metabolism | 11 | | 5 | 7 | | | 7 |
| Valine, leucine and isoleucine degradation | 17 | | 15 | 17 | | | 14 |
| Valine, leucine and isoleucine biosynthesis | 11 | 6 | 6 | 6 | | | 11 |
| Lysine biosynthesis | 11 | 4 | 3 | 3 | 9 | - | 10 |
| Lysine degradation | 14 | | 13 | 12 | | | 13 |
| Arginine and proline metabolism | 26 | | 22 | 21 | 17 | | 20 |
| Histidine metabolism | 17 | | 5 | 7 | | 12 | 12 |
| Tyrosine metabolism | 13 | 19 | 13 | 15 | 5 | | 11 |
| Phenylalanine metabolism | 9 | | 7 | 8 | 5 | | 9 |
| Tryptophan metabolism | 18 | 25 | 15 | 20 | | | 14 |
| Phenylalanine, tyrosine and tryptophan biosynthesis | 22 | 6 | 6 | 6 | 20 | 21 | 21 |
| Biodegradation of Xenobiotics | | | | | | | |
| gamma-Hexachlorocyclohexane degradation | 5 | 5 | 4 | 4 | 4 | 4 | 3 |
| Benzoate degradation via hydroxylation | 2 | 1 | 1 | 1 | 2 | 1 | 1 |
| Tetrachloroethene degradation | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
| 1,4-Dichlorobenzene degradation | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,2-Dichloroethane degradation | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Benzoate degradation via CoA ligation | 8 | 8 | 8 | 6 | 4 | 4 | 7 |
| Styrene degradation | 4 | 4 | 4 | 4 | 1 | 1 | 2 |
| Atrazine degradation | 2 | 1 | 1 | 1 | 1 | 2 | 2 |
| Caprolactam degradation | 1 | 1 | 0 | 1 | 1 | - 1 | 1 |
| Biosynthesis of Secondary Metabolites | | | | | | | |
| Streptomycin biosynthesis | 3 | 3 | 3 | 3 | 3 | 1 | 3 |
| Erythromycin biosynthesis | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
| Terpenoid biosynthesis | 7 | 7 | 5 | 5 | 6 | 6 | 7 |
| Flavonoids, stilbene and lignin biosynthesis | 8 | 4 | 4 | 6 | 3 | 4 | 13 |
| Alkaloid biosynthesis I | 4 | 4 | 4 | 4 | 1 | 2 | 3 |
| Alkaloid biosynthesis II | 2 | 2 | 1 | 1 | 1 | 2 | 3 |
| Carbohydrate Metabolism | | | | | | | |
| Glycolysis / Gluconeogenesis | 26 | 26 | 25 | 22 | 23 | 22 | 25 |
| Citrate cycle (TCA cycle) | 17 | 16 | 14 | 16 | 13 | 13 | 14 |
| Pentose phosphate pathway | 18 | 16 | 16 | 16 | 15 | 15 | 16 |
| Inositol metabolism | 2 | 2 | 2 | 2 | 1 | 1 | 2 |
| Pentose and glucuronate interconversions | 8 | . 7 | 6 | 7 | 6 | 5 | 8 |
| Fructose and mannose metabolism | 18 | 16 | 14 | 15 | 12 | 12 | 17 |
| Galactose metabolism | 13 | 15 | 13 | 11 | 12 | 11 | 12 |
| Ascorbate and aldarate metabolism | 2 | 1 | 2 | 2 | 2 | 2 | 4 |
| Pyruvate metabolism | 31 | 21 | 18 | 20 | 21 | 19 | 28 |
| Glyoxylate and dicarboxylate metabolism | 14 | 9 | 5 | 7 | 9 | 8 | 28 14 |
| Propanoate metabolism | 16 | 15 | 10 | 14 | 6 | 7 | 12 |
| Butanoate metabolism | 17 | 18 | 15 | 16 | 9 | 9 | 12 |
| C5-Branched dibasic acid metabolism | 2 | 2 | 13 | 2 | 1 | 1 | 1 |
| Co Dianonou Giodole dela metabolism | | | 1 | | . 1 | 1 | 1 |

Table 2-2. (Continue)

| | Number of ER | | | | | | |
|---|------------------------------|---------|---------|--------|---------|---------|---------------|
| Metabolic network | ANC H SA DME CEL SCE SPO ATH | | | | | | |
| Energy Metabolism | | | | | | | |
| Oxidative phosphorylation | 7 | 6 | 5 | 6 | 6 | 6 | 6 |
| ATP synthesis | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Photosynthesis | 2 | 2 | 2 | 2 | 1 | 2 | 2 |
| Methane metabolism | 5 | 4 | 3 | 4 | 5 | 4 | 5 |
| Carbon fixation | 19 | 12 | 12 | 12 | 12 | 11 | 20 |
| Reductive carboxylate cycle (CO2 fixation) | 9 | 7 | 5 | 8 | 5 | 4 | 7 |
| Nitrogen metabolism | 19 | 13 | 12 | 13 | 13 | 12 | 16 |
| Sulfur metabolism | 15 | 7 | 5 | 6 | 12 | 10 | 11 |
| Lipid Metabolism | | | | | | | |
| Fatty acid biosynthesis (path 1) | 7 | 8 | 5 | 9 | 9 | 9 | 5 |
| Fatty acid biosynthesis (path 2) | 5 | 5 | 4 | 5 | 4 | 3 | 4 |
| Fatty acid metabolism | 14 | 16 | 15 | 15 | 9 | 7 | 13 |
| Synthesis and degradation of ketone bodies | 5 | 5 | 4 | 5 | 2 | 3 | 3 |
| Sterol biosynthesis | 16 | 15 | 9 | 8 | 12 | 12 | 16 |
| Bile acid biosynthesis | 6 | 11 | 7 | 8 | 5 | 4 | 5 |
| C21-Steroid hormone metabolism | 4 | 9 | 5 | 5 | 2 | 3 | 3 |
| Androgen and estrogen metabolism | 9 | 13 | 7 | 8 | 4 | 5 | 7 |
| Metabolism of Cofactors and Vitamins | | | | | | | |
| Ubiquinone biosynthesis | 4 | 2 | 2 | 2 | 2 | 2 | 4 |
| One carbon pool by folate | 4 16 | 2 16 | 2 12 | 11 | 13 | 2 13 | 4 15 |
| Thiamine metabolism | | 10 | 12 | | 13 4 | 13 4 | |
| Riboflavin metabolism | 5 9 | 5 | 4 | 1 7 | 7 | 8 | 5 |
| Vitamin B6 metabolism | 4 | 5 | 3 | | 4 | 4 | 8 4 |
| Nicotinate and nicotinamide metabolism | 9 | 3 11 | 6 | 3 8 | 7 | 6 | 7 |
| Pantothenate and CoA biosynthesis | 13 | 8 | 6 | 8 | 10 | 10 | 12 |
| Biotin metabolism | 3 | 2 | 2 | 1 | 3 | 2 | 3 |
| Folate biosynthesis | 13 | 10 | 9 | 6 | 10 | 10 | 9 |
| Retinol metabolism | 2 | 2 | 1 | 2 | 0 | 0 | 2 |
| Porphyrin and chlorophyll metabolism | 16 | 15 | 14 | 5 | 11 | 13 | 14 |
| Match allows of Country Control of the | | | | | | | |
| Metabolism of Complex Carbohydrates Starch and sucrose metabolism | 20 | 21 | 10 | 10 | 10 | 16 | 20 |
| N-Glycans biosynthesis | 30 | 21 | 18 | 19 | 18 | 16 | 30 |
| N-Glycan degradation | 11 | 16 | 15 | 12 | 8 | 7 | 11 |
| O-Glycans biosynthesis | 8 2 | 8 5 | 7 2 | 7 3 | 1 0 | 1 | 6 |
| Aminosugars metabolism | 14 | 3 14 | 13 | 12 | 9 | 0 7 | 2 8 |
| Glycosaminoglycan degradation | 4 | 9 | 8 | 6 | 0 | 1 | 4 |
| Chondroitin / Heparan sulfate biosynthesis | 4 | 6 | 3 | 6 | 0 | 0 | 4 |
| Keratan sulfate biosynthesis | 0 | 4 | 3 | 2 | 0 | 0 | 0 |
| Lipopolysaccharide biosynthesis | 3 | 0 | 0 | 0 | 0 | 0 | 3 |
| Peptidoglycan biosynthesis | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
| Matchelian of County I in the | | | | | | | |
| Metabolism of Complex Lipids Glycerolipid metabolism | 33 | 37 | 34 | 33 | 29 | 27 | 30 |
| Inositol phosphate metabolism | 8 | 11 | 10 | 10 | 7 | 5 | 8 |
| Glycosylphosphatidylinositol(GPI)-anchor biosynthesis | 0 | 1 | 0 | 0 | ó | 0 | 0 |
| Sphingophospholipid biosynthesis | 1 | 2 | 2 | 2 | 2 | 1 | ő |
| Phospholipid degradation | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Prostaglandin and leukotriene metabolism | 9 | 15 | 6 | 6 | 5 | 4 | 10 |
| Sphingoglycolipid metabolism | 8 | 12 | 7 | . 9 | 3 | 2 | 5 |
| Blood group glycolipid biosynthesis - lact series | 1 | 5 | í | 2 | 0 | 0 | 1 |
| Blood group glycolipid biosynthesis - neolact series | 2 | 9 | 4 | 5 | 0 | 0 | 2 |
| Globoside metabolism | 5 | ģ | 5 | 4 | í | 1 | 5 |
| Ganglioside biosynthesis | 1 | 5 | 1 | i | Ô | Ô | 1 |

Table 2-2. (Continue)

| | Number of ER | | | | | | |
|--|--------------|------|------------|-----|-----|-----|-----|
| Metabolic network | ANC | H SA | DME | CEL | SCE | SPO | ATH |
| Metabolism of Other Amino Acids | , , | | | | | | |
| beta-Alanine metabolism | 13 | 13 | 9 | 11 | 7 | 7 | 11 |
| Taurine and hypotaurine metabolism | 2 | 5 | 4 | 4 | 2 | . 1 | 2 |
| Aminophosphonate metabolism | 3 | 3 | 3 | 3 | 4 | . 3 | 3 |
| Selenoamino acid metabolism | 14 | 9 | 8 | 10 | 13 | 10 | 10 |
| Cyanoamino acid metabolism | 6 | 5 | 5 | 6 | 5 | 6 | 5 |
| D-Glutamine and D-glutamate metabolism | 2 | 2 | 2 | 2 | 0 | 0 | 1 |
| D-Arginine and D-ornithine metabolism | 1 | 2 | 2 | 2 | 1 | 2 | 1 |
| D-Alanine metabolism | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Glutathione metabolism | 10 | 9 | 10 | 10 | 8 | 8 | 10 |
| Nucleotide Metabolism | | | | | | | |
| Purine metabolism | 56 | 51 | 43 | 46 | 42 | 43 | 46 |
| Pyrimidine metabolism | 36 | 36 | 30 | 33 | 26 | 27 | 32 |
| Nucleotide sugars metabolism | 6 | 7 | 6 | 6 | 3 | 4 | 5 |

In the column of ANC, the number represented a number of ERs found in the common ancestor among all the 6 species. In the column of each species, for a given metabolic network, I estimated how many ERs exist for each of all the 6 species.

Table 2-3. Number of ERs in each category of metabolic networks*

| Categories of metabolic networks | No. of ERs in ancestral ER set* | No. of lost ER** | No. of gained ER* |
|---------------------------------------|---------------------------------|------------------|-------------------|
| Amino Acid Metabolism | 214 | 156 | 32 |
| Biodegradation of Xenobiotics | 24 | 16 | 0 |
| Biosynthesis of Secondary Metabolites | 26 | 17 | 7 |
| Carbohydrate Metabolism | 129 | 74 | 11 |
| Energy Metabolism | 73 | 41 | 4 |
| Lipid Metabolism | 51 | 34 | 18 |
| Metabolism of Cofactors and Vitamins | 88 | 63 | 8 |
| Metabolism of Complex Carbohydrates | 71 | 58 | 27 |
| Metabolism of Complex Lipids | 62 | 35 | 32 |
| Metabolism of Other Amino Acids | 48 | 31 | 6 |
| Nucleotide Metabolism | 86 | 43 | 3 |

^{*}The numbers of ERs were counted at every category of metabolic networks in KEGG.

^{**} These numbers were total numbers of gains or losses of ERs in each categories, respectively.

Table 2-4. Numbers of gains of ERs in lipid and complex lipid metabolism in the vertebrate lineage after the divergence with *D. melanogaster*

| Metabolic networks | The number of the ER gain* |
|---|----------------------------|
| Prostaglandin and leukotriene metabolism | 5(6) |
| Blood group glycolipid biosynthesis - neolact se | 3(7) |
| Ganglioside biosynthesis | 3(4) |
| C21-Steroid hormone metabolism | 2(5) |
| Androgen and estrogen metabolism | 2(4) |
| Globoside metabolism | 2(4) |
| Glycerolipid metabolism | 1(6) |
| Bile acid biosynthesis | 1(5) |
| Sphingoglycolipid metabolism | 1(4) |
| Blood group glycolipid biosynthesis - lact series | 1(4) |
| Fatty acid metabolism | 1(2) |
| Glycosylphosphatidylinositol(GPI)-anchor biosy | 1(1) |
| Fatty acid biosynthesis (path 1) | 0(3) |
| Inositol phosphate metabolism | 0(3) |
| Sphingophospholipid biosynthesis | 0(1) |
| Fatty acid biosynthesis (path 2) | 0(0) |
| Synthesis and degradation of ketone bodies | 0(0) |
| Sterol biosynthesis | 0(0) |
| Phospholipid degradation | 0(0) |

^{*}The numbers of gain in the parentheses represented total numbers of ER gains from the common ancestor among the 6 eukaryotic species to *H. sapiens*.

Table 2-5. Function of products in prostaglandin and leukotriene metabolism

| ER number | Enzymatic reaction | Products | Function | Ref. |
|-----------|------------------------------|---------------|-------------------------------|-------------------------------|
| 14 | prostaglandin-F synthase | 11-epi PGF 2α | Blood pressure | (Liston and Roberts 1985) |
| 82 | arachidonate 12-lipoxygenase | 12-HPETE | Cell proliferation | (Wen et al. 2003) |
| 414 | LTC4 synthase | LTC4 | Constriction of smooth muscle | (Soberman and Christmas 2003) |
| 971 | prostaglandin-D synthase | PGD2 | Chemotaxis, Allergic asthma | (Funk 2001) |
| 972 | PGI2 synthase | PGI2 | Declumping, Vasodilation | (Funk 2001) |
| 973 | thromboxane-A synthase | TXA2 | Vasoconstriction, Aggregation | (Funk 2001) |




Figure 2-1. Estimation of the ancestral gene set and the timing of the gain and loss of ER

ER-A represents one of the enzymatic reactions. In this figure, the state "1" is defined when the species had at least one gene with the ER-A, and "0" is defined when the species had no gene with the ER-A.




Figure 2-2. Phylogenetic tree of 6 eukaryotes

The numbers below the 6 species and the ancestor were total numbers of ERs existing in each organism. The red number indicated the total number of gains of ERs in the branch and the white number indicated the total number of losses of ERs in the branch.

No. of losses of ERs




Figure 2-3. Distribution of total numbers of the gain and loss in ER

Blue bar represents the number of ERs that were only lost in this study. Red bar represents the number of ERs that were gained once and then were lost in this study.




Figure 2-4. Prostaglandin and leukotriene metabolism in H. sapiens

ER colored in white represents that the ER existed in the common ancestor of the 6 eukaryotes examined. ERs colored in yellow or green were observed after the divergence between yeast and animal or invertebrate and vertebrate, respectively. Substrate colored in green represents that it was produced by the ER in the vertebrate lineage after the divergence from *D. melanogaster*. See the Table 2-5 for more detail about the gained ERs and the compounds produced newly by these ERs. ER414 is functional in the metabolic networks of the taurine and hypotaurine metabolism, the selenoamino acid metabolism, the cyanoamino acid metabolism and the glutathione metabolism.




Figure 2-5. Phylogenetic tree of 6 eukaryotes

The numbers below the 6 species and the ancestor were total numbers of ERs existing in each organism. The red number indicated the total number of gains of ERs in the branch and the white number indicated the total number of losses of ERs in the branch.




Figure 2-6. Effect to the numbers of ERs in the common ancestor or gain and loss of ERs in each branch by the topology of the phylogenetic tree

In this figure, the topology between a plant and yeasts were different from Figure 4-1. The numbers below the 6 species and the ancestor were total numbers of ERs existing in each organism. The red number indicated the total number of gains of ERs in the branch and the white number indicated the total number of losses of ERs in the branch.

Chapter 3

Evolution of vitamin B₆ (Pyridoxine) metabolism by gain and loss of genes

3.1 Introduction

In the previous chapter, I examined the gain and loss of ERs in the metabolic networks of the 6 eukaryotes for evaluating their evolutionary process. For this examination, I dealt with only ERs in which the gene products inferred from the complete genome sequence data can possibly work as an enzyme. This is because more than one enzyme is often involved with an ER. However, if I deal with the metabolic network in which I can easily identify the enzymes encoded by particular genes that are involved with the particular ER, I can discuss directly the gain and loss of genes instead of ERs.

In this analysis, I take the Vitamin B₆ (VB6) metabolism as a concrete example because of the basis of the following backgrounds. VB6 functions as a cofactor of many enzymes. In particular, pyridoxal 5'-phosphate (PLP), which is the active form of VB6, has multiple roles as a versatile cofactor of enzymes mainly in the metabolism of amino acid compounds (Grogan 1988; Rottmann *et al.* 1991; Helmreich 1992; Mihara *et al.* 1997; Kack *et al.* 1999). Moreover, VB6 appears to play an important role against photosensitization in fungi (Bilski *et al.* 2000). Most unicellular organisms and plants can biosynthesize PLP by themselves.

Studies of the VB6 metabolism have been conducted in particular in Escherichia

coli (White and Dempsey 1970; Lam and Winkler 1990; Zhao et al. 1995; Yang et al. 1996; Man et al. 1996) and fungi such as Cercospora nicotianae, Neurospora crassa, Aspergillus nidulans, and Saccharomyces cerevisiae (Ehrenshaft et al. 1999; Osmani et al. 1999; Ehrenshaft and Daub 2001; Bean et al. 2001). For the PLP biosynthetic pathways, some of these studies have characterized three pathways and a total of 12 genes involved in the pathways in the bacteria and fungi (Figure 3-1). In the case of E. coli, both de novo and salvage pathways were discovered. The two pathways include the enzymes encoded by 10 genes in total (Mittenhuber 2001). The corresponding de novo pathway has not been discovered in fungi or plants. Instead, fungi were found to have another biosynthesis pathway. This pathway, the fungi-type pathway, has two genes, SNZ and SNO whose functions are unknown. These reports indicate that the species synthesizing PLP have at least one of the three PLP biosynthetic pathways.

Animals such as insects and mammals have to take VB6 compounds as nourishment. In particular, humans take VB6 from meats and vegetables (Manore 2000). This fact suggests that there is a problem for VB6 metabolism in animal lineages. It is conceivable that their PLP biosynthetic pathways became dysfunctional due to the loss of some of the 12 genes in their evolutionary lineages, on the condition that the ancestor of the animals had PLP biosynthetic pathways. Actually, pdxA and pdxJ, which are the members of the 10 genes mentioned above, have not been found in animals (Ehrenshaft *et al.* 1999). Moreover, SNZ and SNO have been reported to be lost in animals except for the marine sponge *Suberites domuncula* (Seack *et al.* 2001). Even though the functions of SNZ and SNO are unknown, they should have a role indispensable in the biosynthetic pathway in fungi. The loss of these two genes has been considered as the cause of the inability for PLP biosynthesis in animal lineages, in

particular in the Eumetazoa lineage.

To study the evolution of the VB6 metabolism, I paid my attention to the three pathways for PLP biosynthesis and the 12 genes involved in these pathways. I was particularly interested to know when individual genes of them were gained or lost in evolution.

In this study, to elucidate the evolutionary processes of VB6 metabolism, I focused on the gain and loss of the 12 genes in 122 species in the three domains of life, eubacteria, archaebacteria and eukaryotes (Woese *et al.* 1990). I estimated a particular gene set of the common ancestor of the 122 species on the basis of their genealogical relationships. Then, I identified the gain and loss events for the genes by comparing the gene sets between the ancestral species and the extant one. On the basis of the results obtained, I will report evolutionary features of the formation and dysfunction processes of VB6 metabolism in the view of gains and losses of the genes.

3.2 Materials and methods

3.2.1 Genes related to the VB6 metabolism

There are 12 genes involved in the PLP biosynthetic pathways of VB6 metabolism; gapA, epd, dxs, pdxA, pdxB, pdxF, pdxH, pdxJ, pdxK, pdxY, SNZ, and SNO (Mittenhuber 2001). GapA is paralogous to epd, and so is pdxK and pdxY, and each pair's functions was also similar in the PLP biosynthetic pathways (Yang $et\ al.\ 1998a$; Yang $et\ al.\ 1998b$). From this reason, I regarded epd as gapA, and pdxY as pdxK. Thus, I studied the total of 10 genes instead of 12 genes for the VB6 metabolism.

In order to identify the genes in the VB6 metabolism in the complete genome sequences of 122 species (9 eukaryotes, 16 archaebacteria, and 97 eubacteria) (Table 3-1), BLAST homology searches for the 10 genes were performed against them (Altschul et al. 1990). As query sequences, I used the protein sequences of gapA (the accession number of b1779), dxs (b0420), pdxA (b0052), pdxB (b2320), pdxF (b0907), pdxH (b1638), pdxJ (b2564), and pdxK (b2418) that were derived from E. coli K-12 MG1655, and SNZ (NP_013814) and SNO (NP_013813) that were derived from S. cerevisiae. If I could not find any of the 10 genes by the homology search against the complete sequences of a species, I assumed that the species did not have it. Thereafter, I compared my results with the KEGG Orthology (KO) dataset in KEGG database (Bono et al. 1998; Kanehisa et al. 2002), in order to make my results more reliable. The KO dataset contains orthologous gene families that are categorized on the basis of experimental information, sequence homology, and gene order in the genome. If a gene was not related to the VB6 metabolism, I removed it from my dataset.

3.2.2 Phylogenetic tree

I used phylogenetic trees that were revised based on those of Baldauf et al. (2000) and Nelson et al. (2000) to estimate the gene sets which were involved with VB6 metabolism of the ancestor of the 122 species (See the next section). Because some of eubacterial and archaebacterial species examined were not included in those trees, I estimated the genealogical relationships by constructing a phylogenetic tree in the subdivision of eubacteria and archaebacteria. To do so I applied their 16s rRNA sequences to the CLUSTALW program with 1,000 bootstrap trials (Thompson et al. 1994). I excluded the positions with gaps and corrected for multiple substitutions.

3.2.3 Estimation of the gene set of the VB6 metabolism in the ancestor

I assumed that a single gene was acquired only once during evolution of the 122 species examined in this model, ignoring horizontal gene transfer and parallel evolution. I show the method for estimating the set of genes in the ancestor. This method is exactly the same as the method used in the previous chapter except that a gene instead of an ER is discussed in this study. In Figure 3-2, I used the following two states for representing whether a species had a particular gene (Gene-A): the state "1" is used when the species had at least one homologous gene with Gene-A, and "0" is used when the species had no homologous gene with Gene-A.

If the states of two species are the same, namely (0,0) or (1,1), I assume that the ancestor has the same state (Patterns 1 and 2 in Figure 3-2). If the state is different between the two closest species compared, namely (0,1) or (1,0), I use the states for all of the species that were located in the outside of the two comparing species in the tree and out-group species. Let me denote a group of those species by species group C. If

at least one species in Group C has the state of "1", I regard the ancestral state as "1" (Pattern 3 in Figure 3-2). If all species of group C have the state of "0", I regard the ancestral state as "0" (Pattern 4 in Figure 3-2). In this way, I estimated the states for a given gene at all internal-nodes.

3.2.4 The order of the losses among the genes

Using the result of the estimation of gene loss, I investigated the order of the losses among the 10 genes. For any pair of the 10 genes, I examined which was lost earlier during evolution of the 122 species. I statistically tested the frequency of the order of gene loss by the binominal distribution. If the losses of two genes occurred on the same branch in the phylogenetic tree, I did not count them because I did not know which gene lost earlier than the other.

3.3 Results

3.3.1 Comparison of the gene sets among species

For the VB6 metabolism, the three PLP biosynthetic pathways have been reported as mentioned earlier; the *de novo* pathway and the salvage pathway in *E. coli* (the bacterial-type) and the fungi-type pathway. When I examined whether the 10 genes existed in the 122 species whose genome sequences were completely or almost completely determined, I found that no species had all genes (Table 3-1). Moreover, 7 genes, *gapA*, *dxs*, *pdxA*, *pdxB*, *pdxF*, *pdxH*, and *pdxJ*, for the *de novo* pathway were found only in 17 eubacteria. These bacterial species were all gamma-proteobacteria, indicating the the *de novo* pathway may be functioning only in gamma-proteobacteria.

3.3.2 Distribution of the genes in the three domains of life

Based on the gene sets of the 122 species, I compared the gene sets among the three domains of life (Figure 3-3). Since SNZ, SNO and pdxF were observed in all domains, these genes were considered to exist before the divergence into the three domains. This result indicates that the fungi-type pathway composed by SNZ and SNO was formed before the divergence into the three domains. Other 4 genes, gapA, dxs, pdxH and pdxK, in the bacterial-type pathways were discovered in eukaryotes and eubacteria. This result means that part of the bacterial-type pathways was found in eukaryotes and eubacteria. Based on my assumption that a single gene was acquired only once during evolution of the 122 species examined, I interpret this result as indicating that the salvage pathway composed by pdxH and pdxK was formed before the divergence into the three domains. I also note that PdxA, pdxB, and pdxJ were

observed only in eubacteria. When I focused on the eubacteria group, I found that both pdxA and pdxJ were observed not only in Proteobacteria but also Firmicutes, Cyanobacteria, Chlorobi and Aquificae. On the other hand, pdxB existed only in gamma-proteobacteria. Therefore, I consider that both pdxA and pdxJ were generated in eubacterial lineage after the divergence from the other two domains and that pdxB was generated in the gamma-proteobacterial lineage after the divergence from the other lineages. These three genes are thus considered to contribute to the formation of the de novo pathway in the eubacterial lineage. In particular, pdxB may be the most important gene for the completion of this pathway because it is considered that this gene was generated only in gamma-proteobacteria.

3.3.3 Estimation of the losses of genes

Because the gene sets of the VB6 metabolism were different among the 122 species examined, it was considered that the loss as well as gain of genes had occurred in the 10 genes. I thus examined how many losses of the 10 genes had occurred in the evolution of the 122 species. To estimate the occurrence of the gain or loss of a particular gene in each evolutionary lineage from the common ancestor to the extant species, I needed to estimate whether the gene had existed in the common ancestor of the 122 species. Using the phylogenetic tree in Figure 3-4, I estimated the ancestral gene set of each node. As a result, I found that the total of 133 losses of genes had occurred during the evolution from the common ancestor of the 122 species (Table 3-2). The numbers of losses of gapA, pdxB, and pdxJ were 3, 3 and 8, respectively. These numbers were all smaller than those of losses of the other seven genes. In the case of gapA, a less number of gene losses may be explained by the following functional

constraint: GapA functions not only in VB6 metabolism but also in glycolysis (Seta et al. 1997), and therefore, the functional constraint of gapA is not expected to be lost. Since I estimated that pdxB had emerged in the gamma-proteobacterial lineage, I did not need to count the number of losses of the genes before the divergence of this lineage from the other lineages. Therefore, it was considered that the total numbers of losses of this gene were smaller than those of the other genes. In the case of pdxJ, I estimated that this gene emerged in eubacterial lineage and was lost in an early period in the particular lineages of the 97 eubacterial species. The total number of loss of pdxJ was smaller than those of the other genes, because this gene did not exist for a long time in the particular lineages.

3.3.4 Losses of SNO and SNZ in Animal lineages

The genes of SNO and SNZ were reported only in the sponge S. domuncula among Metazoa. By homology search against the genome sequences of six animals (Homo sapiens, Mus musculs, Rattus nurvegicus, Ciona intestinalis, Caenorhabditis elegans and Drosophila melanogaster), I found that these two genes exist in C. intestinalis. In addition, the positions of the two genes on the genome of C. intestinalis, in which they aligned head to head, were also the same as those in S. domuncula, S. cerevisiae and S. pombe (Table 3-3). In the case of eubacteria and archaebacteria, SNO was next to SNZ on the genomes of the 33 species studied. However, the two genes were aligned head to tail on all the 33 genomes. Therefore, it is reasonable that SNO and SNZ in C. intestinalis had not been transferred from bacterial species. From these results, I conclude that SNO and SNZ had existed in the Eumetazoan lineage, and the losses of SNO and SNZ occurred at least three times

independently in C. elegans, D. melanogaster, and vertebrate lineages (Figure 3-4).

3.3.5 Correlation of losses of genes among PLP biosynthetic pathways

I have found that the loss of *SNZ* occurred together with that of *SNO* in the same branch more often than other pairs of genes (Table 3-4). As I mentioned above, the two genes were often present side by side on the genome. Moreover, the two genes function only in the fungi-type pathway. These observations support that the losses of the two genes occurred at the same time.

Next, I examined the order of losses for the 10 genes. When I compared the order of losses between two genes, a significant bias was observed in particular in 9 combinations of genes; pdxH amd dxs, pdxJ and pdxH, pdxH and pdxF, pdxA and dxs, pdxJ and pdxA, pdxJ and dxs, pdxJ and pdxK, pdxJ and SNO, pdxK and pdxF (Table 3-4). In every pair of the 9 combinations, I observed that the loss of the latter gene occurred more frequently after the loss of the former gene. These biases were statistically significant against the binominal distribution (P < 0.05). From this result, I depicted the patterns of loss of the 5 genes in Figure 3-5. The loss of pdxJ caused the loss of at least one of pdxA, pdxH and pdxK as shown in the figure. These four genes encode the enzymes whose reactions are connected through the substance called pyridoxine 5'-phosphate (PNP). Moreover, the losses of these four genes caused the loss of at least one of pdxF and dxs. These two genes encode the enzymes whose reactions are connected to pdxA and pdxJ through 4-phosphohydroxy-L-threonine (4PHT) or 1-deoxyxyluiose 5-phosphate (DXP), respectively. If I call two genes encoding the enzymes that catalyze two consecutive reactions the neighbor genes, I would thus conclude that the loss of a gene accelerates the loss of the neighbor gene.

3.4 Discussion

To my knowledge, I have made the first attempt to elucidate the evolution of VB6 metabolism focusing on the gain and loss of the 10 genes involved in the PLP biosynthetic pathways. On the assumption that one of the genes was acquired only once during the evolution of the whole 122 species, I found that every gene in the VB6 metabolism had been lost more than once in the evolutionary lineages of the 122 species. This result suggests that the breakdown of the VB6 metabolism by gene loss might have occurred in many lineages, which should be examined by experiments.

I have also revealed three aspects in the evolution of VB6 metabolism by estimating the gain and loss of the 10 genes. One is related to the evolutionary order of the generations of three PLP biosynthetic pathways. From the distribution of the 10 genes over the 122 species examined, I found that the fungi-type and the salvage pathway were possibly older than the *de novo* pathway on the basis of the following two results. First, *pdxK* and *pdxH* in the salvage pathway exist only in eubacteria and eukaryotes, while *SNO* and *SNZ* in the fungi-type pathway are found in the three domains, eubacteria, archeabacteria, and eukaryotes. Therefore, I consider that both the fungi-type and the salvage pathways have existed before the separation of three domains of life. Second, I have found that *pdxB* in the *de novo* pathway exists only in gamma-proteobacteria indicating that this gene was generated in gamma-proteobacteria after the divergences of the three domains of life.

Applying the second result mentioned above to the existing model for explaining the evolution of the metabolic networks, the patchwork model and the *de novo* invention model (Jensen 1976; Schmidt *et al.* 2003), I have proposed the process of the

formation of the *de novo* pathway in gamma-proteobacteria as follows (Figure 3-6). Originally, the common ancestor of the 97 bacterial species studied had a part of the *de novo* pathway which had 5 genes, *dxs, pdxA, pdxF, pdxH,* and *pdxJ*. Because *gapA* functioned not only in pyridoxine biosynthesis but also in glycolysis (Seta *et al.* 1997), I think that this gene had also existed in the common ancestor. As shown Figure 3-6, when *pdxB* was generated in the lineage of gamma-proteobacteria, the reaction catalyzed by the product of *pdxB* was connected to the two enzymatic reactions that were respectively catalyzed by the products of *gapA* and *pdxF*. As a result, the *de novo* pathway was completed by the 7 genes, *dxs, gapA, pdxA,pdxB, pdxF, pdxH,* and *pdxJ* in gamma-proteobacteria. I have reached the same conclusion as Mittenhuber's (Mittenhuber 2001) but in a different way. He has explained the reason why the *de novo* pathway was largely restricted to gamma-proteobacteria on the basis of the functions of the two genes, *pdxA* and *pdxJ*, and the requirement of VB6 in the *de novo* pathway.

However, I could not answer which of the fungi-type and salvage pathways was established earlier as the PLP biosynthetic pathway, because I could not estimate the times when pdxK, pdxH, SNO and SNZ were originated in this study. In other words, I could not determine which gene sets of the two pathways have been generated earlier.

The second aspect is related to the losses of SNO and SNZ in animal lineages. In animals, the two genes have been discovered only in the marine sponge, S. domuncula (Seack et al. 2001). Therefore, it is plausible that the losses of SNZ and SNO occurred only once in the Eumetazoa lineage after its divergence from the Porifera lineage. I have found that there were the two genes in the complete genome sequence of C. intestinalis in the present study. This species is more closely related with mammals

than *D. melanogaster* and *C. elegans* both of which do not have the two genes (Figure 3-4). Therefore, I consider that *SNZ* and *SNO* had existed in the animals after the divergence between invertebrate and vertebrate, and the losses of them occurred independently at least three times in the animal lineage, as shown in Figure 3-4. I reject the possibility of horizontal gene transfer from the bacterial lineage to *C. intestinalis* not only by the homology of the two genes but also by the order and the direction of the two genes on the genome (Table 3-3).

The third aspect is related to the evolutionary order of the gene loss. As shown in Figure 3-5, the losses of the 5 genes occurred in that order in the figure during the evolution of the VB6 metabolism. Historically, five models have been proposed to explain the formation of metabolic pathways; the retrograde model, the patchwork model, *de novo* invention, specialization of a multifunctional enzyme and pathway duplication (Horowitz 1945; Jensen 1976; Schmidt *et al.* 2003). However, these models consider gene gain only. Since there are other reports that gene loss also have often occurred in the metabolic pathways in bacterial lineages (Tatusov *et al.* 1996; Shigenobu *et al.* 2000), it is not sufficient to consider the gain of genes only for the evolution of metabolic pathways in the prokaryotic lineages.

Therefore, I propose a new model based on my results that explain the evolution of metabolic pathways by gene loss. Once the loss of a gene occurred in a metabolic pathway, the neighboring gene is more easily lost than the other genes in the pathway. This could be explained by functional constraint. The breakdown of a metabolic pathway by gene loss will decrease the functional constraints of the other genes of the pathway. My model tells that the functional constraint decreases more extensively in the proximal genes to the lost gene than in the distant ones. Of course, it is possible

that the functional constraint is affected by others. For example, if a gene is involved also in another metabolic pathway such as gapA, its functional constraint can not be changed.

My approach for the estimation of the gain and loss of genes is affected at least by two points. First, in this study, I did not take into account horizontal gene transfer or parallel evolution. In other words, I have considered that gene gain occurred only once, while gene loss could have occurred more than once in the evolution of the 122 species Therefore, if there is a difference in a gene set among closely related examined. species, the number of gene losses is expected to be larger than that of gene gains. horizontal gene transfer and parallel evolution occurred, gene loss would decrease whereas gene gain would increase. When I have the evidence for horizontal gene transfer and parallel evolution of the 10 genes in this study, it is possible to estimate more accurately the time of gain and loss of the genes. Second, my results are affected by the topology of a phylogenetic tree. If the topology is changed, the estimation of the evolutionary times of the gain and loss of genes are accordingly changed. result, it is possible to miscount the total number of gains or losses of genes. However, my results showed that the sets of genes are different between the 122 species examined (Table 3-1). Since the gain and loss of genes cause of the differentiation of the set of genes in the species, my conclusion that the evolutionary process of VB6 metabolism had been quite dynamic in the events of gain and loss of genes, under some constraints, is not fluctuated, even though the topology of the phylogenetic tree changes.

Reported studies using the comparative analysis have often shown the difference in a gene set involved in the metabolic pathways among species (Huynen *et al.* 1999). By the estimation of the gain and loss of genes, I would be able to know not only the

difference in a metabolic pathway among species examined but also the answer to the following question as to in which lineage the change in a metabolic pathway occurred in evolution. This means that I will understand the evolutionary processes of the metabolic networks by gains and losses of genes. In some of the metabolic pathways, dysfunctions in particular lineages are reported (Smirnoff 2001; Meganathan 2001). By applying my approach to these metabolic pathways, I will be able to elucidate the dysfunctions of the pathways by the gain and loss of genes. It is also possible that I further extend my approach to the other metabolic networks in the KEGG (Kanehisa *et al.* 2002) and EcoCyc (Karp *et al.* 2002) database, to understand more clearly the evolutionary process of the metabolic pathways included in them.

Table 3-1. 10 Gene families related to the vitamin B6 metabolism in the 122 species

| Symbol | Species name | gapA | pdxB | pdxF | dxs | pdxA | pdxJ | pdxK | pdxH | SNZ | SNO |
|--------|---|---------------------------------------|---------|---------|---------|--------------------|---------|--------------------|---------|-----|-----|
| ECJ | Escherichia coli K-12 W3110 | JW1413 JW1414 JW1768 *JW2894 | JW2317 | JW0890 | JW0410 | JW0051 | JW2548 | JW1628 JW2411 | JW1630 | | |
| ECO | Escherichia coli K-12 MG1655 | b1416 b1417 b1779 *b2927 | b2320 | b0907 | b0420 | b0052 | b2564 | b1636 b2418 | b1638 | | |
| SFL | Shigella flexneri 301 (serotype 2a) | SF1444 SF1795 SF1796 *SF2912 | SF2396 | SF0902 | SF0357 | SF0049 | SF2626 | SF1661 SF2473 | SF1663 | | |
| ECE | Escherichia coli O157:H7 EDL933Bacteria | Z2304 Z2818 *Z4266 | Z3582 | Z1253 | Z0523 | Z0061 | Z3845 | Z2648 Z3684 | Z2652 | | |
| ECS | Escherichia coli O157:H7 Sakai | ECs2022 ECs2488 *ECs3798 | ECs3204 | ECs0990 | ECs0474 | ECs0057 | ECs3430 | ECs2345 ECs3290 | ECs2347 | | |
| ECC | Escherichia coli CFT073 | c1843 c2184 *c3505 | c2865 | c1045 | c0531 | c0065 c0764 | c3088 | c2028 c2953 | c2030 | | |
| STM | Salmonella typhimurium LT2 | STM1290 | STM2370 | STM0977 | STM0422 | STM0091 STM0163 | STM2578 | STM1450 STM2435 | STM1448 | | |
| STY | Salmonella typhi | STY1825 | STY2601 | STY0977 | STY0461 | STY0106 STY0185 | STY2824 | STY1672 STY2672 | STY1674 | | |
| STT | Salmonella typhi Ty2 | t1169 | t0494 | t1957 | t2441 | t0094 t0168 | t0279 | t1318 | t1316 | | |
| YPE | Yersinia pestis CO92 | YPO2157 | YPO2763 | YPO1389 | YPO3177 | YPO0493 | YPO2930 | YPO2368 | YPO2370 | | |
| YPK | Yersinia pestis KIM | y2165 | y1597 | y2784 | y1008 | y3682 | | y1967 | y1965 | | |
| BUC | Buchnera sp. APS | BU298 | | BU312 | BU464 | | | | | | |
| BAS | Buchnera aphidicola Sg | BUsg287 | | BUsg302 | BUsg448 | | | | | | |
| BAB | Buchnera aphidicola Bp | bbp276 | | bbp289 | | | | | | | |
| WBR | Wigglesworthia brevipalpis | Wbr0018 | Wbr0458 | | Wbr0633 | Wbr0118 | Wbr0578 | | Wbr0428 | | |
| VPA | Vibrio parahaemolyticus | VP2157 VP2970 *VP2601 | VP2193 | VP1247 | VP0686 | VP0337 | VP2569 | VPA1632 | VPA1730 | | |
| VVU | Vibrio vulnificus CMCP6 | VV11141 VV13140 *VV11539 | VV11988 | VV12813 | VV10315 | VV10662 | VV11568 | VV21237 | VV21122 | | |

Table 3-1. (Continue)

| | Species name | gapA | pdxB | pdxF | dxs | pdxA | pdxJ | pdxK | pdxH | SNZ | SNO |
|-----|---|--------------|--------|------------|-----------|--------------|------------|------------|------------|--------|--------|
| /CH | Vibrio cholerae El Tor N16961 | VC1069 | VC2108 | VC1159 | VC0889 | VC0444 | VC2458 | | VCA1079 | | |
| | | VC2000 | | | | | | | | | |
| | | *VC0476 | | | | | | | | | |
| ON | Shewanella oneidensis MR-1 | SO0538 | SO3071 | SO2410 | SO1525 | SO3638 | SO1351 | | SO2895 | | |
| | | SO2345 | | | | | | | | | |
| | | *SO0931 | | | | | | | | | |
| IIN | Haemophilus influenzae Rd KW20Bacteria | HI0001 | | HI1167 | HI1439 | | | HI0405 | HI0863 | HI1647 | HI1648 |
| MU | Pasteurella multocida PM70 | PM0924 | | PM0837 | PM0532 | PM1650 | | PM0290 | | PM1232 | PM1233 |
| AΕ | Pseudomonas aeruginosa PA01 | PA3195 | PA1375 | PA3167 | PA4044 | PA0593 | PA0773 | PA5516 | PA1049 | | |
| | | *PA0551 | | | | PA2212 | | | | | |
| PU | Pseudomonas putida KT2440 | PP1009 | PP2117 | PP1768 | PP0527 | PP0402 | PP1436 | PP5357 | PP1129 | | |
| | | *PP4964 | | | | | | | | | |
| ΚAC | Xanthomonas axonopodis | XAC3352 | | XAC1648 | XAC2565 | XAC0864 | XAC0012 | XAC1524 | XAC3009 | | |
| CC | Xanthomonas campestris pv. | XCC3192 | | XCC1589 | XCC2434 | XCC0792 | XCC0012 | XCC1476 | XCC2840 | | |
| KFA | Xylella fastidiosa 9a5c | XF0457 | | XF2326 | XF2249 | XF0839 | XF0060 | | XF1337 | | |
| ŒT | Xylella fastidiosa Temecula1 | PD1626 | | PD1358 | PD1293 | PD1834 | PD0040 | | PD0583 | | |
| ME | Neisseria meningitidis MC58 | NMB0207 | | NMB1640 | NMB1867 | NMB0195 | NMB0448 | | NMB1360 | | |
| | • | NMB2159 | | | | | | | | | |
| NMA | Neisseria meningitidis Z2491 | NMA0062 | | NMA1894 | NMA0589 | NMA0072 | NMA2037 | | NMA1572 | | |
| | | NMA0246 | | | | | | | | | |
| RSO | Ralstonia solanacearum GMI1000 | RS00105 | | RS04512 | RS01378 | RS04975 | RS04138 | | RS01771 | | |
| | | | | | | | | | RS05086 | | |
| ATU | Agrobacterium tumefaciens C58 (Uwash/Dupo | ont) Atu3737 | | Atu3707 | Atu0745 | Atu1104 | Atu2024 | Atu2487 | Atu0760 | | |
| | | | | | | Atu5073 | | | | | |
| ATC | Agrobacterium tumefaciens C58 (Cereon) | AGR_L_2195 | | AGR_L_2260 | AGR_C_135 | I AGR_C_2043 | AGR_C_3668 | AGR_C_4518 | AGR_C_1381 | | |
| | , | | | | | AGR_pAT_104 | . – – | | | | |
| SME | Sinorhizobium meliloti 1021 | SMc03979 | | SMc00640 | SMc00972 | SMb20146 | SMc01407 | SMc04084 | SMc00069 | | |
| | | | | | | SMb20772 | | | | | |
| | | | | | | SMc00580 | | | | | |
| BME | Brucella melitensis 16M | BMEI0310 | | BMEI0347 | BMEI1498 | BMEI1266 | BMEI0621 | BMEI0221 | BMEI1517 | | |
| 3MS | Brucella suis 1330 | BR1728 | | BR1687 | BR0436 | BR0683 | BR1385 | BR1830 | BR0416 | | |
| MLO | Mesorhizobium loti MAFF303099 | mlr3750 | | mll3876 | mlr7474 | mll7861 | mll1418 | mlr4132 | ml17454 | | |
| BJA | Bradyrhizobium japonicum | bll1523 | | bl17402 | bl12651 | bll4103 | bl15064 | blr4233 | bl12624 | | |
| | | | | | | blr3887 | | | | | |
| | | | | | | blr4374 | | | | | |
| CCR | Caulobacter crescentus CB15 | CC3248 | | CC3216 | CC2068 | CC1686 | CC1557 | CC0256 | CC0918 | | |
| RCO | Rickettsia conorii Malish 7 | | | | | | | | | | |
| RPR | Rickettsia prowazekii Madrid E | | | | | | | | | | |

Table 3-1. (Continue)

| Symbo | l Species name | gapA | pdxB | pdxF | dxs | pdxA | pdxJ | pdxK | pdxH | SNZ | SNO |
|-------|----------------------------------|-------------|------|----------|---------|---------|---------|---------|---------|---------|---------|
| HPJ | Helicobacter pylori J99 | jhp0855 | | | jhp0328 | jhp1490 | jhp1489 | | | | |
| | | jhp1265 | | | | | | | | | |
| HPY | Helicobacter pylori 26695 | HP0921 | | | HP0354 | HP1583 | HP1582 | | | | |
| | | HP1346 | | | | | | | | | |
| CJE | Campylobacter jejuni NCTC11168 | Cj1403c | | Cj0326 | Cj0321 | Cj1239 | Cj1238 | | | | |
| CPJ | Chlamydophila pneumoniae J138 | gapA | | | tktB_2 | | | | | | |
| CPA | Chlamydophila pneumoniae AR39 | CP0123 | | | CP0790 | | | | | | |
| CPN | Chlamydophila pneumoniae | CPn0624 | | | CPn1060 | | | | | | |
| CMU | Chlamydia muridarum | TC0792 | | | TC0608 | | | | | | |
| CTR | Chlamydia trachomatis serovar D | CT505 | | | CT331 | | | | | | |
| ANA | Anabaena sp. PCC 7120 | all2566 | | all1683 | alr0599 | alr4755 | all0218 | | all1248 | | |
| | | all5062 | | | | | | | | | |
| | | alr1095 | | | | | | | | | |
| TEL | Thermosynechococcus elongatus | tl10043 | | | tl10623 | tl12045 | tlr0838 | | tll0331 | | |
| | | tll1466 | | | | | | | | | |
| SYN | Synechocystis sp. PCC 6803 | slr0884 | | | sll1945 | sll0660 | slr1779 | | sll1440 | | |
| CTE | Chlorobium tepidum TLS | CT1480 | | | CT0337 | CT0591 | CT0331 | | | | |
| BBU | Borrelia burgdorferi B31 | BB0057 | | | | | | BB0768 | | | |
| TPA | Treponema pallidum Nichols | TP0844 | | | TP0824 | | | | | | |
| LIL | Leptospira interrogans 56601 | LA1704 | | LA0366 | LA3285 | LA0800 | LA1514 | | LA1166 | | |
| SPM | Streptococcus pyogenes MGAS8232 | spyM18_0261 | | | | | | | | | |
| SPY | Streptococcus pyogenes SF370 | SPy0274 | | | | | | | | | |
| SPG | Streptococcus pyogenes SGAS315 | SpyM3_0201 | | | | | | | | | |
| SPS | Streptococcus pyogenes SSI-1 | SPs0207 | | | | | | | | | |
| SAG | Streptococcus agalactiae 2603 | SAG1768 | | | | | | | | SAV6830 | SAV6831 |
| SAN | Streptococcus agalactiae NEM316 | gbs1811 | | gbs1621 | | | | | | | |
| SPR | Streptococcus pneumoniae R6 | spr1825 | | | | | | | | spr1322 | spr1321 |
| SPN | Streptococcus pneumoniae TIGR4 | SP2012 | | | | | | | | SP1468 | SP1467 |
| SMU | Streptococcus mutans UA159 | SMU.360 | | SMU.1656 | | | | | | | |
| LLA | Lactococcus lactis subsp. lactis | L0004 | | L0083 | L108911 | | | | | | |
| | | L0005 | | | L123365 | | | | | | |
| LPL | Lactobacillus plantarum WCFS1 | lp_0789 | | lp_0204 | lp_2610 | | | lp_0863 | | | |
| SAM | Staphylococcus aureus MW2 | MW0734 | | | | | | | | MW0474 | MW0475 |
| | | MW1630 | | | | | | | | | |
| SAU | Staphylococcus aureus N315, | SA0727 | | | | | | | | SA0477 | SA0478 |
| | | SA1510 | | | | | | | | | |
| SAV | Staphylococcus aureus Mu50, | SAV0772 | | | | | | | | SAV0519 | SAV0520 |
| | | SAV1687 | | | | | | | | | |
| SEP | Staphylococcus epidermidis | SE0557 | | | | | | | | SE2262 | SE2261 |
| | | SE1361 | | | | | | | | | |

Table 3-1. (Continue)

| Symbo | l Species name | gapA | pdxB | pdxF | dxs | pdxA | pdxJ | pdxK | pdxH | SNZ | SNO |
|-------|--|------------|------|----------|----------|--------|---------|----------|---------|---------|---------|
| BSU | Bacillus subtilis 168 | BG10827 | | BG12673 | BG11715 | | | | | BG10075 | BG10076 |
| | | BG12592 | | | | | | | | | • |
| BHA | Bacillus halodurans C-125 | BH3149 | | BH1188 | BH2779 | BH0804 | | | | BH0022 | BH0023 |
| | | BH3560 | | | | | | | | | |
| LIN | Listeria innocua CLIP 11262 | lin2553 | | lin2957 | lin1402 | | | | | lin2205 | lin2206 |
| LMO | Listeria monocytogenes EGD-e | lmo2459 | | lmo2825 | lmo1365 | | | | | lmo2101 | lmo2102 |
| OIH | Oceanobacillus iheyensis HTE831 | OB2160 | | | | OB1013 | | | | OB2687 | OB2686 |
| | | OB2438 | | | | | | | | | |
| CAC | Clostridium acetobutylicum | CAC0709 | | | CAC2077 | | | CAC1622 | | CAC0594 | CAC0595 |
| | | | | | CAC0106 | | | | | | |
| CTC | Clostridium tetani E88 | CTC00378 | | | CTC01575 | | | CTC00497 | | | |
| CPE | Clostridium perfringens 13 | CPE1304 | | | CPE1819 | | | CPE2318 | | | |
| MPN | Mycoplasma pneumoniae M129 | A05_orf337 | | | | | | | | | |
| MGE | Mycoplasma genitalium G-37 | MG301 | | | | | | | | | |
| UUR | Ureaplasma urealyticum serovar 3 | | | | | | | | | | |
| MPE | Mycoplasma penetrans HF-2 | MYPE8170 | | | MYPE730 | | | | | | |
| MPU | Mycoplasma pulmonis UAB CTIP | MYPU_0460 | | | | | | | | | |
| TTE | Thermoanaerobacter | TTE1762 | | | TTE1298 | | | | | TTE0823 | TTE0822 |
| MTC | Mycobacterium tuberculosis CDC1551 | MT1480 | | MT0907 | MT2756 | | | | MT2682 | MT2681 | MT2679 |
| MTU | Mycobacterium tuberculosis H37Rv | Rv1436 | | Rv0884c | Rv2682c | | | | Rv2607 | Rv2606c | rV2604c |
| | | | | | Rv3379c | | | | | | |
| MLE | Mycobacterium leprae TN | ML0570 | | ML2136 | ML1038 | | | | ML2131 | ML0450 | ML0474 |
| CEF | Corynebacterium efficiens YS-314 | CE1706 | | CE0903 | CE1796 | | | CE0975 | | CE1779 | |
| CGL | Corynebacterium glutamicum | NCgl0900 | | NCgl0794 | NCgl1827 | | | NCgl0876 | | Cgl0788 | Cgl0789 |
| | | NCgl1526 | | | | | | | | | |
| SCO | Streptomyces coelicolor A3(2) | SCO1947 | | SCO4366 | SCO6768 | | | | SCO4387 | SCO1523 | SCO1522 |
| | | SCO7511 | | | | | | | | | |
| TWH | Tropheryma whipplei Twist | TW300 | | | TW484 | | | | | TW264 | TW265 |
| TWS | Tropheryma whipplei TW08/27 | TW472 | | | TW280 | | | | | TW506 | TW505 |
| BLO | Bifidobacterium longum NCC2705Bacteria | BL1363 | | BL1660 | BL1132 | | | BL0934 | | BL1146 | BL1145 |
| FNU | Fusobacterium nucleatum | FN0652 | | | FN1208 | FN0226 | | | | FN1463 | |
| | | | | | FN1464 | | | | | | |
| DRA | Deinococcus radiodurans R1 | DR1343 | | | DR1475 | | | DRA0184 | DR0495 | DR1367 | DR1366 |
| TMA | Thermotoga maritima MSB8 | TM0688 | | | TM1770 | | | | | TM0473 | TM0472 |
| AAE | Aquifex aeolicus VF5 | aq_1065 | | | aq_881 | aq_852 | aq_1423 | | • | | |
| SSO | Sulfolobus solfataricus | | | | | | | | | SSO0570 | SSO0571 |
| STO | Sulfolobus tokodaii strain7 | | | | | | | | | ST1441 | ST1442 |
| APE | Aeropyrum pernix K1 | | | | | | | | | APE0246 | APE0244 |
| PAI | Pyrobaculum aerophilum IM2 | | | | | | | | | PAE2819 | PAE2820 |

0

Table 3-1. (Continue)

| Symbo | Species name | gapA | pdxB | pdxF | dxs | pdxA | pdxJ | pdxK | pdxH | SNZ | SNO |
|-------|--------------------------------|---|------|------------------------|-----------|------|------|------------------------|--------------|--------------|--------------|
| MMA | Methanosarcina mazei Goel | | | MM2911 | | | | | | MM2432 | MM2433 |
| MAC | Methanosarcina acetivorans C2A | | | MA2304 | | | | | | MA1567 | MA1566 |
| HAL | Halobacterium sp. NRC-1 | | | | | | | | | VNG1793C | VNG2598G |
| TVO | Thermoplasma volcanium GSS1 | | | | | | | | | TVG1050816 | TVG0059350 |
| TAC | Thermoplasma acidophilum | | | | | | | | | Ta0522 | Ta0009 |
| MTH | Methanobacterium | | | | | | | | | MTH666 | MTH190 |
| AFU | Archaeoglobus fulgidus VC-16 | | | | | | | | | AF0508 | AF0509 |
| MJA | Methanococcus jannaschii | | | | | | | | | MJ0677 | MJ1661 |
| PHO | Pyrococcus horikoshii OT3 | | | | | | | | | PH1355 | PH1354 |
| PAB | Pyrococcus abyssi GE5 | | | | | | | | | PAB0537 | PAB0538 |
| PFU | Pyrococcus furiosus DSM 3638 | | | | | | | | | PF1529 | PF1528 |
| MKA | Methanopyrus kandleri AV19 | | | | | | | | | MK1371 | MK1062 |
| HSA | Homo sapiens | G3P2_HUMAN G3PT HUMAN | | SERC_HUMA | N | | | PDXK_HUMAN | NP_060599 | | |
| MMU | Mus musuculus | G3P_MOUSE G3PT MOUSE | | NP_932136 | | | | NP_742146 | NP_598782 | | |
| RNO | D-44 | _ | | VD 227251 | | | | ND 112057 | ND 070102 | | |
| KINO | Rattus novegicus | G3P_RAT NP 076454 | | XP_227251 XP_215179 | | | | NP_113957 | NP_072123 | | |
| CIN | Ciona intesitinalis | ci0100132109 | | ci0100142284 | | | | ci0100152209 | ci0100131648 | ci0100145397 | ci0100145416 |
| | | *************************************** | | ***************** | | | | 010100102007 | 0.0100101010 | 0.01001.0057 | 0.01001.0.10 |
| DME | Drosophila melanogaster | CG12055-PA | | CG11899-PA | | | | CG4446-PA | | | |
| | | CG8893-PA | | | | | | | | | |
| | | CG9010-PA | | | | | | | | | |
| CEL | Caenorhabditis elegans | F33H1.2 | | F26H9.5 | | | | F57C9.1a | F57B9.1 | | |
| | č | K10B3.7 | | | | | | | | | |
| | | K10B3.8 | | | | | | | | | |
| | | T09F3.3 | | | | | | | | | |
| SCE | Saccharomyces cerevisiae | YGR192C | | YOR184W | | | | NP_010885 | YBR035C | NP 013814 | NP_013813 |
| | • | YJL052W | | | | | | NP 014424 | | NP 014066 | NP 014065 |
| | | YJR009C | | | | | | - | | NP 116596 | NP_116595 |
| SPO | Schizosaccharomyces pombe | SPBC354.12 | | SPAC1F12.07 | | | | NP_593904 NP_588389 | SPAC1093.02 | SPAC29B12.04 | |
| ATH | Arabidopsis thaliana | At1g12900 | | At2g17630 | At3g21500 | | | At5g37850 | At5g49970 | At2g38230 | At5g60540 |
| 42111 | Andrewpois manana | At1g13440 | | At4g35630 | At4g15560 | | | Ang. 1000 | AU8477/0 | At3g16050 | TINEOUN-40 |
| | | At1g153440 At1g16300 | | Vid822020 | At5g11380 | | | | | At5g01410 | |
| | | At1g16300 At1g42970 | | | ADS11380 | | | | | ADS01410 | |
| | | | | | | | | | | | |
| | | At1g79530 | | | | | | | | | |
| | | At3g04120 | | | | | | | | | |
| | | At3g26650 | | | | | | | | | |

^{*} Genes were named epd in KEGG database.

Table 3-2. Distribution and number of losses of the 10 genes

| Gene name | No. of species | No. of gene loss |
|-----------|----------------|------------------|
| dxs | 76 | |
| gapA | 103 | 3 |
| pdxA | . 46 | 13 |
| pdxB | 17 | 3 |
| pdxF | 67 | 24 |
| pdxH | 52 | 14 |
| pdxJ | 42 | 8 |
| pdxK | 45 | 20 |
| SNO | 46 | 20 |
| SNZ | 48 | 18 |

Table 3-3. Order between SNZ and SNO on the genome

| Garaina | CNTZ | | -44 | | CNIC | - 1 | ataut a | n d | |
|---------|--------------|-----|----------|----------|-------------|--------|----------------|-------------|----------|
| Species | SNZ | +- | start er | | SNO | +- | start e: 33818 | nd 34408 | * |
| BHA | BH0022 | + | 32914 | | BH0023 | | | 1389181 | |
| BLO | BL1146 | - | 1390876 | 1389905 | | - | 1389819 | | |
| BSU | BG10075 | + | 19060 | | BG10076 | + | 19966 | 20556 | |
| CAC | CAC0594 | + | 686139 | | CAC0595 | + | 687014 | 687574 | • |
| CEF | CE1779 | - | 1877157 | 1876264 | | | 921071 | 922572 | <u>.</u> |
| CGL | Cg10788 | + | 831021 | | Cgl0789 | + | 831971 | 832573 | |
| DRA | DR1367 | - | 1373812 | | DR1366 | - | 1372892 | 1372302 | r |
| FNU | FN1463 | + | 2145142 | 2145984 | | | | | |
| HIN | HI1647 | + | 1712590 | 1713465 | | + | 1713517 | 1714044 | |
| LIN | lin2205 | + | 2226138 | 2227025 | | + | 2227027 | 2227593 | |
| LMO | lmo2101 | + | 2181329 | | lmo2102 | . + | 2182218 | 2182784 | * |
| MLE | ML0450 | - | 551116 | | ML0474 | + | 575469 | 576140 | |
| MTC | MT2681 | - | 2930234 | 2929314 | MT2679 | - | 2928432 | 2927836 | |
| MTU | Rv2606c | - | 2934068 | 2933169 | Rv2604c | - | 2932287 | 3921691 | |
| OIH | OB2687 | - | 2757867 | 2756980 | OB2686 | - | 2756929 | 2756354 | * |
| PMU | PM1232 | + | 1424316 | 1425203 | PM1233 | + | 1425206 | 1425787 | * |
| SAG | SAV6830 | + | 8154087 | 8155001 | SAV6831 | + | 8155015 | 8155620 | * |
| SAM | MW0474 | + | 548163 | 549050 | MW0475 | + | 549054 | 549614 | * |
| SAU | SA0477 | + | 557598 | 558485 | SA0478 | + | 558489 | 559049 | * |
| SAV | SAV0519 | + | 581847 | 582734 | SAV0520 | + | 582738 | 583298 | * |
| SCO | SCO1523 | _ | 1628367 | 1627456 | SCO1522 | _ | 1627443 | 1626835 | * |
| SEP | SE2262 | _ | 2330773 | 2329886 | SE2261 | - | 2329883 | 2329326 | * |
| SPN | SP1468 | - | 1381373 | 1380498 | | _ | 1380497 | 1379916 | * |
| SPR | spr1322 | _ | 1309261 | 1308368 | | _ | 1308367 | 1307786 | |
| TMA | TM0473 | _ | 500776 | | TM0472 | _ | 499891 | 499891 | |
| TTE | TTE0823 | _ | 830528 | | TTE0822 | _ | 829648 | 829079 | |
| TWH | TW264 | + | 348455 | | TW265 | + | 349318 | 349884 | |
| TWS | TW506 | _ | 544896 | | TW505 | _ | 544033 | 543467 | |
| 1 1115 | 1 11 300 | | 311070 | 311033 | 1 11 202 | | 5.7000 | - 10 101 | |
| AFU | AF0508 | + | 466652 | 467662 | AF0509 | + | 467659 | 468255 | * |
| APE | APE0246 | _ | 177978 | | APE0244 | _ | 176917 | 176357 | |
| HAL | VNG1793C | + | 1326538 | | VNG2598G | _ | 1943348 | 1942737 | |
| MAC | MA1567 | _ | 1856725 | | MA1566 | _ | 1855406 | 1854807 | * |
| MJA | MJ0677 | _ | 604189 | | MJ1661 | _ | 1644079 | 1643519 | |
| MKA | MK1371 | _ | 1400016 | | MK1062 | + | 1030519 | 1031127 | |
| MMA | MM2432 | + | 2901968 | | MM2433 | + | 2903175 | 2903786 | * |
| MTH | MTH666 | - | 593940 | | MTH190 | + | 134383 | 134961 | |
| PAB | PAB0537 | + | 747283 | | PAB0538 | + | 748321 | 748911 | * |
| PAI | PAE2819 | + | 1666365 | | PAE2820 | + | 1667372 | 1667986 | |
| PFU | PF1529 | | 1426935 | 1425928 | | | 1425896 | 1525303 | |
| PHO | PH1355 | - | 1222832 | 1221825 | | _ | 1221796 | 1221206 | |
| SSO | | | | | SSO0571 | + | 503620 | 504222 | |
| | SSO0570 | + | 502607 | | | | 1447239 | 1447841 | |
| STO | ST1441 | + | 1446232 | 1447242 | | + | | | |
| TAC | Ta0522 | - | 551548 | | Ta0009 | + | 8957 | 9568 | |
| TVO | TVG1050816 | - | 1051826 | 1050826 | TVG0059350 |) + | 58751 | 59350 | |
| ATH | At5g01410 | _ | 173504 | 172575 | At5g60540 | - | 23632473 | 23630700 | |
| | At2g38230 | + | 15960019 | 15960948 | • | | | | |
| | At3g16050 | _ | 5445065 | 5444121 | | | | | |
| SCE | NP 013814 | + | 458407 | | NP 013813 | - | 457958 | 457284 | * |
| JCL | NP 14066 | + | 13267 | | NP 014065 | | 12876 | 12208 | |
| | NP 116596 | + | 11363 | | NP 116595 | _ | 10301 | 10969 | |
| SPO | SPAC29B12.0 | | 5376387 | | SPAC222.08 | - - | 968574 | 967870 | |
| SDO | AJ27952 | , ' | 55/030/ | 3311411 | AJ277953 | - | 700274 | | * |
| | | , | 40522 | 27601 | | 6 | 41897 | 44025 | |
| CIN | ci0100145397 | | 40522 | 3/084 | ci010014541 | U | 4109/ | 44023 | |

⁺⁻ represented that the gene was on the sense strand or the antisense strand, respectively.

^{*}SNZ and SNO are neighbors on the genome.

Table 3-4. Patterns of gene losses between two genes


| 1 | 2 | Same branch ^a | 1 only** | 2 only** | 1 to 2*** | 2 to 1*** |
|------|------|--------------------------|----------|----------|-----------|-----------|
| pdxH | pdxA | 5 | 9 | 8 | 5 | 3 |
| pdxH | dxs | 1 | 13 | 9 | 8 | 0 |
| pdxH | pdxJ | 5 | 9 | 3 | 0 | 6 |
| pdxH | pdxB | 1 | 13 | 2 | 0 | 1 |
| pdxH | gapA | 0 | 14 | 3 | 1 | 1 |
| pdxH | pdxK | 6 | 8 | 14 | 4 | 3 |
| pdxH | serC | 7 | 7 | 17 | 7 | 1 |
| pdxH | SNZ | 2 | 12 | 16 | 8 | 4 |
| pdxH | SNO | 3 | 11 | 17 | 9 | 4 |
| pdxA | dxs | 1 | 12 | 9 | 7 | 0 |
| pdxA | pdxJ | 5 | 8 | 3 | 0 | 9 |
| pdxA | pdxB | 1 | 12 | 2 | 0 | 1 |
| pdxA | gapA | 0 | 13 | 3 | 1 | 1 |
| pdxA | pdxK | 3 | 10 | 17 | 5 | 4 |
| pdxA | serC | 6 | 7 | 18 | 4 | 1 |
| pdxA | SNZ | 0 | 13 | 18 | 8 | 3 |
| pdxA | SNO | 0 | 13 | 20 | 9 | 3 |
| dxs | pdxJ | i | 9 | 7 | 0 | 8 |
| dxs | pdxB | 0 | 10 | 3 | 0 | 1 |
| dxs | gapA | i | 9 | 2 | 0 | 1 |
| dxs | pdxK | ī | 9 | 19 | 0 | 3 |
| dxs | serC | 3 | 7 | 21 | 2 | 5 |
| dxs | SNZ | 0 | 10 | 18 | 6 | 5 5 |
| dxs | SNO | 0 | 10 | 20 | 6 | 5 |
| pdxJ | pdxB | 2 | 6 | 1 | Ō | 0 |
| pdxJ | gapA | $\bar{0}$ | 8 | 3 | 2 | i |
| pdxJ | pdxK | 2 | 6 | 18 | 8 | 2 |
| pdxJ | serC | 5 | 3 | 19 | 6 | 0 |
| pdxJ | SNZ | Õ | 8 | 18 | 8 | 3 |
| pdxJ | SNO | ŏ | 8 | 20 | 10 | 3 |
| pdxB | gapA | ŏ | 3 | 3 | 0 | Ō |
| pdxB | pdxK | ŏ | 3 | 20 | ŏ | ĭ |
| pdxB | serC | ŏ | 3 | 24 | ŏ | 0 |
| pdxB | SNZ | ŏ | 3 | 18 | ŏ | ĭ |
| pdxB | SNO | ŏ | 3 | 20 | ŏ | i |
| gapA | pdxK | ŏ | 3 | 20 | 3 | Ô |
| gapA | serC | ő | 3 | 24 | 1 | ĭ |
| gapA | SNZ | 2 | 1 | 16 | Ô | î |
| gapA | SNO | 2 | 1 | 18 | ŏ | i |
| pdxK | serC | 5 | 15 | 19 | ğ | 2 |
| pdxK | SNZ | 3 | 17 | 15 | 4 | 7 |
| pdxK | SNO | 4 | 16 | 16 | 4 | 7 |
| serC | SNZ | 2 | 22 | 16 | 3 | 7 |
| serC | SNO | 2 | 22 | 18 | 4 | 7 |
| SNZ | SNO | 18 | 0 | 2 | 0 | ó |
| DINT | PINO | 19 | V | | υ | |

^{*} Same branch indicated that the loss of the two genes had occurred in the same node.

^{** 1} only indicated that the loss of the gene in the first column had occurred and 2 only indicated that the loss of the gene in the second column

^{*** 1} to 2 indicated that the loss of gene in the first column had occurred before the loss of gene in the second column, and 2 to 1 indicated that the loss of gene in the second column had occurred before the loss of gene in the first column.

A



Pathways discovered in bacteria Pathway discovered in yeast Figure 3-1. VB6 metabolism

A: PNP biosynthetic pathways. Circle indicated the substrates. PLP was an active

form of VB6. *1: 3-Hydroxy-4-phophohydroxy-alpha-ketobutyrate *2:

Glyceraldehyde-3-phosphate

B: Chemical structure of PLP and vitamin B₆




Figure 3-2. Estimation of the ancestral gene set by comparing the gene set in two species

In this figure, I used the two following states for representing whether the species had the Gene-A: the state "1" when the species had at least one gene with the Gene-A, and "0" when the species had no gene with the Gene-A.




Figure 3-3. Distribution of 10 genes related to VB6 metabolism




Figure 3-4. (Continue)




Figure 3-4. Genealogical relationships of 122 species

A: a genealogical relationship of 97 eubacteria. B: a genealogical relationship of 16 archaebacteria. C: a genealogical relationship of 9 eukaryotes. Red arrows on the branches represented the losses of *SNZ* and *SNO*.





Figure 3-5. Loss of the 5 genes in VB6 metabolism

The pathway is a part of the *de novo* and the salvage pathways. The gene colored in black (pdxJ) was lost at first. The genes colored in red (pdxA, pdxH), and pdxK) were lost secondary. The genes colored in blue (dxs) and pdxF were lost thirdly. Circle indicated the substrates. *1: 3-Hydroxy-4-phophohydroxy-alpha-ketobutyrate *2: Glyceraldehyde-3-phosphate



Pathways discovered in bacteria Figure 3-6. Formation of VB6 metabolism

The genes colored in red and blue were the primary genes for VB6 biosynthesis. The genes colored in black were generated in eubacteria. Circle indicated the substrates.

PLP was an active form of VB6. *1: 3-Hydroxy-4-phophohydroxy-alpha-ketobutyrate *2: Glyceraldehyde-3-phosphate

Chapter 4

Conclusion

In this thesis, I focused upon the evolutionary process of the metabolic networks on the basis of gains and losses of the genes or the enzymatic reactions (ERs). From the studies in the chapters 2 and 3, I made an attempt to answer the following questions, as I mentioned in the chapter 1: How have the biological networks evolved and how were they diversified by genomic changes during evolution?

First, in the chapter 2, I studied the evolution of the metabolic networks for the 6 eukaryotic species whose complete genomes have been sequenced. In particular, I examined the evolutionary process of the metabolic networks from the viewpoint of the gain and loss of ERs, using the genome sequence data. My results have clearly shown that both gains and losses of ERs have occurred many times during evolution of the 6 eukaryotic species. Moreover, the loss of ERs was found to have occurred almost five times as frequently as the gain of ERs, so that the loss of ERs affected greatly evolutionary diversification of the metabolic networks in the eukaryotic species. This may give an explanation about why the heterotrophy is ubiquitously observed in a variety of the species, particularly animals. For the vertebrate lineages after their divergence from the insects such as *D. melanogaster*, however, I found a drastic increase in the occurrence frequency of the gain of ERs in the evolution of metabolic networks. In particular, 41% of the ER gains were deeply involved with the lipid and complex lipid metabolisms. Because some products of these two metabolisms function as hormones, I concluded that the ER gains of the two metabolisms accelerated the

development of hormonal signal transduction for the elaborated regulation of a physiological system during the evolution of vertebrates.

Second, I focused on the evolution of vitamin B₆ metabolism (the PLP biosynthetic pathways), as an example, among the 122 species in the three domains, eubacteria, archaebacteria and eukaryotes, of life. Here, I used the complete genome sequence data of the 122 species for identifying the genes encoding the relevant enzymes in this metabolic pathway. As shown in the chapter 3, I found that all the 10 genes related to this metabolism had been lost more than once during evolution of the 122 species examined. This result suggests that the vitamin B₆ metabolism has changed dynamically the set of genes by the events of gene loss. Taking into account the results of the gain and loss events, I speculated the mechanisms of formation and dysfunction of the PLP biosynthetic pathways. For formation of the pathway, I explained the formation process of the pathway by the known models, the patch work model and the *de novo* invention model. Moreover, I also explained the dysfunctional process of the pathway by a particular order of gene losses. Of course, the validity and versatility of these models to the other networks have to be evaluated in the future study.

As shown in this study, taking the advantage of utilizing the complete genome sequences, I successfully estimated the existence and the absence of particular genes in a species by conducting the comparative studies of different species of organisms.

Finally, I would like to make emphasis of that this line of studies will give us an important insight into the understanding of the evolutionary process of the metabolic networks.

References

Akman L, Yamashita A, Watanabe H, Oshima K, Shiba T, Hattori M, Aksoy S. (2002) Genome sequence of the endocellular obligate symbiont of tsetse flies, Wigglesworthia glossinidia. *Nat. Genet.* **32**:402-407.

Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. (1990) Basic local alignment search tool. *J. Mol. Biol.* **215**:403-10.

Baldauf SL, Roger AJ, Wenk-Siefert I, Doolittle WF. (2000) A kingdom-level phylogeny of Eukaryotas based on combined protein data. *Science* **290**:972-927.

Bean LE, Dvorachek WH Jr, Braun EL, Errett A, Saenz GS, Giles MD, Werner-Washburne M, Nelson MA, Natvig DO. (2001) Analysis of the pdx-1 (snz-1/sno-1) region of the Neurospora crassa genome: correlation of pyridoxine-requiring phenotypes with mutations in two structural genes. *Genetics*. **157**:1067-1075.

Bilski P, Li MY, Ehrenshaft M, Daub ME, Chignell CF. (2000) VB6 (pyridoxine) and its derivatives are efficient singlet oxygen quenchers and potential fungal antioxidants. *Photochem. Photobiol.* **71**:129-134.

Bono H, Ogata H, Goto S, Kanehisa M. (1998) Reconstruction of amino acid biosynthesis pathways from the complete genome sequence. *Genome Res.* **8**:203-210.

Bono H, Goto S, Fujibuchi W, Ogata H, Kanehisa M. (1998) Systematic Prediction of Orthologous Units of Genes in the Complete Genomes. *Genome Inform. Ser. Workshop Genome Inform.* **9**:32-40.

Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG. (2001) Massive gene decay in the leprosy bacillus. *Nature* 409:1007-1111.

Covert MW, Schilling CH, Famili I, Edwards JS, Goryanin II, Selkov E, Palsson BO. (2001) Metabolic modeling of microbial strains in silico. *Trends Biochem. Sci.* **26**:179-186.

Dubey RK, Oparil S, Imthurn B, Jackson EK. (2002) Sex hormones and hypertension. *Cardiovasc. Res.* **53**:688-708.

Ehrenshaft M, Bilski P, Li MY, Chignell CF, Daub ME. (1999) A highly conserved sequence is a novel gene involved in de novo VB6 biosynthesis. *Proc. Natl. Acad. Sci. USA.* **96**:9374-938.

Ehrenshaft M, Daub ME. (2001) Isolation of PDX2, a second novel gene in the pyridoxine biosynthesis pathway of eukaryotes, archaebacteria, and a subset of eubacteria. *J. Bacteriol.* **183**:3383-3390.

Ellis LB, Hou BK, Kang W, Wackett LP. (2003) The University of Minnesota Biocatalysis/Biodegradation Database: post-genomic data mining. *Nucleic. Acids Res.* 31:262-265.

Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, *et al.* (1995) Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. *Science* **269**:496-512.

Forst CV, Schulten K. (2001) Phylogenetic analysis of metabolic pathways. *J. Mol. Evol.* **6**:471-489.

Funk CD. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* **294**:1871-1875.

Gaasterland T, Selkov E. (1995) Reconstruction of metabolic networks using incomplete information. *Proc. Int. Conf. Intell. Syst. Mol. Biol.* 3:127-135.

Galagan JE, Calvo SE, Borkovich KA, Selker EU, Read ND, Jaffe D, FitzHugh W, Ma LJ, Smirnov S, Purcell S, Rehman B, Elkins T, Engels R, Wang S, Nielsen CB, Butler J, Endrizzi M, Qui D, Ianakiev P, Bell-Pedersen D, Nelson MA, Werner-Washburne M, Selitrennikoff CP, Kinsey JA, Braun EL, Zelter A, Schulte U, Kothe GO, Jedd G, Mewes W, Staben C, Marcotte E, Greenberg D, Roy A, Foley K, Naylor J, Stange-Thomann N, Barrett R, Gnerre S, Kamal M, Kamvysselis M, Mauceli E, Bielke C, Rudd S, Frishman D, Krystofova S, Rasmussen C, Metzenberg RL, Perkins DD, Kroken S, Cogoni C, Macino G, Catcheside D, Li W, Pratt RJ, Osmani SA, DeSouza CP, Glass L, Orbach MJ, Berglund JA, Voelker R, Yarden O, Plamann M, Seiler S, Dunlap J, Radford A, Aramayo R, Natvig DO, Alex LA, Mannhaupt G, Ebbole DJ, Freitag M, Paulsen I, Sachs MS, Lander ES, Nusbaum C, Birren B. (2003) The genome sequence of the filamentous fungus Neurospora crassa. *Nature* 422:859-868.

Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. (2003) ExPASy: The proteomics server for in-depth protein knowledge and analysis. *Nucleic. Acids Res.* 31:3784-3788.

Fumoto M, Miyazaki S, Sugawara H. (2002) Genome Information Broker (GIB): data retrieval and comparative analysis system for completed microbial genomes and more. *Nucleic. Acids Res.* **30**:66-68.

Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. (2003) ExPASy: The proteomics server for in-depth protein knowledge and analysis. *Nucleic. Acids Res.* 31:3784-3788.

Grogan DW. (1988) Temperature-sensitive murein synthesis in an Escherichia coli pdx mutant and the role of alanine racemase. *Arch. Microbiol.* **150**:363-367.

Helmreich EJ. (1992) How pyridoxal 5'-phosphate could function in glycogen phosphorylase catalysis. *Biofactors*. **3**:159-172.

Himmelreich R, Hilbert H, Plagens H, Pirkl E, Li BC, Herrmann R. (1996) Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae. *Nucleic. Acids Res.* **24**:4420-4449.

Horowitz N. H. (1945) On the evolution of biochemical synthesis. *Proc. Natl. Acad. Sci. USA.* **31**:152-157.

Huber J, Gruber C. (2001) Immunological and dermatological impact of progesterone. *Gynecol. Endocrinol.* **15**:18-21.

Huynen MA, Dandekar T, Bork P. (1999) Variation and evolution of the citric-acid cycle: a genomic perspective. *Trends. Microbiol.* 7:281-291.

Jain R, Rivera MC, Moore JE, Lake JA. (2002) Horizontal gene transfer in microbial genome evolution. *Theor. Popul. Biol.* **61**:489-495.

Jensen R. A. (1976) Enzyme recruitment on evolution of new function. *Annu. Rev. Microbiol.* **30**:409-425.

Jeong H, Tombor B, Albert R, Oltvai ZN, Barabasi AL. (2000) The large-scale organization of metabolic networks. *Nature* **407**:651-654.

Kack H, Sandmark J, Gibson K, Schneider G, Lindqvist Y. (1999) Crystal structure of diaminopelargonic acid synthase: evolutionary relationships between pyridoxal-5'-phosphate-dependent enzymes. *J. Mol. Biol.* **291**:857-876.

Kanehisa M, Goto S, Kawashima S, Nakaya A. (2002) The KEGG databases at GenomeNet. *Nucleic. Acids Res.* **30**:42-46.

Karp PD, Riley M, Paley SM, Pellegrini-Toole A. (2002) The MetaCyc Database. *Nucleic. Acids Res.* **30**:59-61.

Karp PD, Riley M, Saier M, Paulsen IT, Collado-Vides J, Paley SM, Pellegrini-Toole A, Bonavides C, Gama-Castro S. (2002) The EcoCyc Database. *Nucleic. Acids Res.* **30**:56-58.

Kolesnick R, Fuks Z. (2003) Radiation and ceramide-induced apoptosis. *Oncogene*. **22**:5897-5906.

Lam HM, Winkler ME. (1990) Metabolic relationships between pyridoxine (VB6) and serine biosynthesis in Escherichia coli K-12. *J. Bacteriol.* **172**:6518-6528.

Lawrence JG. (2002) Gene transfer in bacteria: speciation without species? *Theor. Popul. Biol.* **61**:449-460.

Lazcano A, Miller SL. (1999) On the origin of metabolic pathways. *J. Mol. Evol.* **49**:424-431.

Lee TI, Rinaldi NJ, Robert F, Odom DT, Bar-Joseph Z, Gerber GK, Hannett NM, Harbison CT, Thompson CM, Simon I, Zeitlinger J, Jennings EG, Murray HL, Gordon DB, Ren B, Wyrick JJ, Tagne JB, Volkert TL, Fraenkel E, Gifford DK, Young RA. (2002) Transcriptional regulatory networks in Saccharomyces cerevisiae. *Science* **298**:799-804.

Liston TE, Roberts LJ 2nd. (1985) Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. *Proc. Natl. Acad. Sci. USA.* **82**:6030-6034.

Man TK, Zhao G, Winkler ME. (1996) Isolation of a pdxJ point mutation that bypasses the requirement for the PdxH oxidase in pyridoxal 5'-phosphate coenzyme biosynthesis in Escherichia coli K-12. *J. Bacteriol.* **178**:2445-2449.

Manore MM. (2000) Effect of physical activity on thiamine, riboflavin, and VB6 requirements. *Am. J. Clin. Nutr.* **72**:598S-606S.

Meganathan R. (2001) Biosynthesis of menaquinone (vitamin K2) and ubiquinone (coenzyme Q): a perspective on enzymatic mechanisms. *Vitam. Horm.* **61**:173-218

Mihara H, Kurihara T, Yoshimura T, Soda K, Esaki N. (1997) Cysteine sulfinate desulfinase, a NIFS-like protein of Escherichia coli with selenocysteine lyase and cysteine desulfurase activities. Gene cloning, purification, and characterization of a novel pyridoxal enzyme. *J. Biol. Chem.* **272**:22417-22424.

Mittenhuber G (2001) Phylogenetic analyses and comparative genomics of VB6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways. *J. Mol. Microbiol. Biotechnol.* 3:1-20

Nelson KE, Paulsen IT, Heidelberg JF, Fraser CM. (2000) Status of genome projects for nonpathogenic bacteria and archaea. *Nat. Biotechnol.* **18**:1049-1054.

Osmani AH, May GS, Osmani SA. (1999) The extremely conserved pyroA gene of Aspergillus nidulans is required for pyridoxine synthesis and is required indirectly for resistance to photosensitizers. *J. Biol. Chem.* **274**:23565-23569.

Oshima K, Kakizawa S, Nishigawa H, Jung HY, Wei W, Suzuki S, Arashida R, Nakata D, Miyata SI, Ugaki M, Namba S. (2003) Reductive evolution suggested from the complete genome sequence of a plant-pathogenic phytoplasma. *Nat. Genet.* Epub.

Overbeek R, Larsen N, Pusch GD, D'Souza M, Selkov E Jr, Kyrpides N, Fonstein M, Maltsev N, Selkov E. (2000) WIT: integrated system for high-throughput genome sequence analysis and metabolic reconstruction. *Nucleic. Acids Res.* **28**:123-125.

Peregrin-Alvarez JM, Tsoka S, Ouzounis CA. (2003) The phylogenetic extent of metabolic enzymes and pathways. *Genome Res.* 13:422-427.

Read TD, Peterson SN, Tourasse N, Baillie LW, Paulsen IT, Nelson KE, Tettelin H, Fouts DE, Eisen JA, Gill SR, Holtzapple EK, Okstad OA, Helgason E, Rilstone J, Wu M, Kolonay JF, Beanan MJ, Dodson RJ, Brinkac LM, Gwinn M, DeBoy RT, Madpu R, Daugherty SC, Durkin AS, Haft DH, Nelson WC, Peterson JD, Pop M, Khouri HM, Radune D, Benton JL, Mahamoud Y, Jiang L, Hance IR, Weidman JF, Berry KJ, Plaut RD, Wolf AM, Watkins KL, Nierman WC, Hazen A, Cline R, Redmond C, Thwaite JE, White O, Salzberg SL, Thomason B, Friedlander AM, Koehler TM, Hanna PC, Kolsto AB, Fraser CM. (2003) The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. *Nature* 423:81-86.

Reeds PJ, Garlick PJ. (2003) Protein and amino acid requirements and the composition of complementary foods. *J. Nutr.* **133**:2953S-2961S.

Rottmann WH, Peter GF, Oeller PW, Keller JA, Shen NF, Nagy BP, Taylor LP, Campbell AD, Theologis A. (1991) 1-aminocyclopropane-1-carboxylate synthase in tomato is encoded by a multigene family whose transcription is induced during fruit and floral senescence. *J. Mol. Biol.* **222**:937-961.

Salzberg SL, White O, Peterson J, Eisen JA. (2001) Microbial genes in the human genome: lateral transfer or gene loss? *Science* **292**:1903-1906.

Schuster S, Fell DA, Dandekar T. (2000) A general definition of metabolic pathways useful for systematic organization and analysis of complex metabolic networks. *Nat. Biotechnol.* **18**:326-332.

Schmidt S, Sunyaev S, Bork P, Dandekar T. (2003) Metabolites: a helping hand for pathway evolution? *Trends Biochem. Sci.* **28**:336-341

Seack J, Perovic S, Gamulin V, Schroder HC, Beutelmann P, Muller IM, Muller WE. (2001) Identification of highly conserved genes: SNZ and SNO in the marine sponge Suberites domuncula: their gene structure and promoter activity in mammalian cells(1). *Biochim. Biophys. Acta.* **1520**:21-34.

Seta FD, Boschi-Muller S, Vignais ML, Branlant G. (1997) Characterization of Escherichia coli strains with gapA and gapB genes deleted. *J. Bacteriol.* **179**:5218-5221.

Shigenobu S, Watanabe H, Hattori M, Sakaki Y, Ishikawa H. (2000) Genome sequence of the endocellular bacterial symbiont of aphids Buchnera sp. APS. *Nature* **407**:81-86.

Smirnoff N. (2001) L-ascorbic acid biosynthesis. Vitam. Horm. 61:241-266.

Soberman RJ, Christmas P. (2003) The organization and consequences of eicosanoid signaling. *J. Clin. Invest.* 111:1107-1113.

Tatusov RL, Mushegian AR, Bork P, Brown NP, Hayes WS, Borodovsky M, Rudd KE, Koonin EV. (1996) Metabolism and evolution of Haemophilus influenzae deduced from a whole-genome comparison with Escherichia coli. *Curr. Biol.* **6**:279-291.

Thompson JD, Higgins DG, Gibson TJ. (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic. Acids Res.* 11:4673-4680.

Tweeddale H, Notley-McRobb L, Ferenci T. (1998) Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. *J. Bacteriol.* **180**:5109-5116.

Unger RH, Orci L. (2002) Lipoapoptosis: its mechanism and its diseases. *Biochim. Biophys. Acta.* **1585**:202-212.

Wen Y, Gu J, Peng X, Zhang G, Nadler J. (2003) Overexpression of 12-lipoxygenase and cardiac fibroblast hypertrophy. *Trends Cardiovasc. Med.* **13**:129-136.

White RS, Dempsey WB. (1970) Purification and properties of VB6 kinase from Escherichia coli B. *Biochemistry* **9**:4057-4064.

Woese CR, Kandler O, Wheelis ML. (1990) Towards a natural system of organisms: proposal for the domains Archaea, Bacteria, and Eucarya. *Proc. Natl. Acad. Sci. USA*. **87**:4576-4579.

Winkel-Shirley B. (2002) Biosynthesis of flavonoids and effects of stress. *Curr. Opin. Plant Biol.* **5**:218-223.

Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL. (1999) A vital role for glycosphingolipid synthesis during development and differentiation. *Proc. Natl. Acad. Sci. USA.* **96**:9142-9147.

Yang Y, Zhao G, Winkler ME. (1996) Identification of the pdxK gene that encodes pyridoxine (VB6) kinase in Escherichia coli K-12. *FEMS Microbiol. Lett.* **141**:89-95.

Yang Y, Zhao G, Man TK, Winkler ME. (1998a) Involvement of the gapA- and epd (gapB)-encoded dehydrogenases in pyridoxal 5'-phosphate coenzyme biosynthesis in Escherichia coli K-12. *J. Bacteriol.* **180**:4294-9.


Yang Y, Tsui HC, Man TK, Winkler ME. (1998b) Identification and function of the pdxY gene, which encodes a novel pyridoxal kinase involved in the salvage pathway of pyridoxal 5'-phosphate biosynthesis in Escherichia coli K-12. *J. Bacteriol.* **180**:1814-21.


Zhao G, Pease AJ, Bharani N, Winkler ME. (1995) Biochemical characterization of gapB-encoded erythrose 4-phosphate dehydrogenase of Escherichia coli K-12 and its possible role in pyridoxal 5'-phosphate biosynthesis. *J. Bacteriol.* 177:2804-2812.

| Enzyme involved with the ER | H SA DME CEL SCE SPO |
|--|--|
| Alcohol dehydrogenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 3-Oxoacyl-[acyl-carrier-protein] reductase Retinol dehydrogenase | |
| L-Iditol 2-dehydrogenase | i i i i i |
| 3beta-Hydroxy-delta5-steroid dehydrogenase | 1 1 1 1 |
| 11beta-Hydroxysteroid dehydrogenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Sepiapterin reductase 3-Hydroxybutyryl-CoA dehydrogenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 2-Dehydropantoate 2-reductase | 0 0 0 1 1 |
| Carbonyl reductase (NADPH) | 1 1 1 1 |
| Prostaglandin-F synthase Prostaglandin-E2 9-reductase | $egin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 5-Amino-6-(5-phosphoribosylamino)uracil reductase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| Cinnamyl-alcohol dehydrogenase | 0 0 0 0 0 |
| Alcohol dehydrogenase(NADP+) | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| Xanthine dehydrogenase IMP dehydrogenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Aldehyde reductase | <u>i i</u> i i i |
| Dihydrokaempferol 4-reductase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| UDPglucose 6-dehydrogenase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| Histidinol dehydrogenase Shikimate 5-dehydrogenase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| Glyoxylate reductase | 1 0 0 0 |
| L-Lactate dehydrogenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| GDP-L-fucose synthase Homoserine dehydrogenase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| 3-Hydroxybutyrate dehydrogenase | 1 1 1 0 1 |
| 3-Hydroxyisobutyrate dehydrogenase | 1 1 1 0 0 |
| Hydroxymethylglutaryl-CoA reductase (NADPH) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 3-Hydroxyacyl-CoA dehydrogenase Malate dehydrogenase | 1 1 1 0 0 1 1 1 1 1 |
| Malate dehydrogenase (oxaloacetate-decarboxylating) | 1 0 0 1 1 |
| Malate dehydrogenase (decarboxylating) | 0 0 0 0 |
| (R,R)-Butanediol dehydrogenase Malate dehydrogenase (oxaloacetate-decarboxylating)(NADP+) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Isocitrate dehydrogenase (NAD+) | 1 1 1 1 |
| Isocitrate dehydrogenase (NADP+) | 1 1 1 1 1 |
| Phosphogluconate dehydrogenase (decarboxylating) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Glucose 1-dehydrogenase Glucose-6-phosphate 1-dehydrogenase | $egin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 3alpha-Hydroxysteroid dehydrogenase (B-specific) | |
| Glycerol dehydrogenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Estradiol 17beta-dehydrogenase Glyoxylate reductase (NADP+) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Glycerol-3-phosphate dehydrogenase(NAD+) | i i i i i |
| Malate dehydrogenase (NADP+) | 0 0 0 0 0 |
| 3-Isopropylmalate dehydrogenase | $egin{bmatrix} 0 & 0 & 0 & 0 & 1 & 1 \\ 0 & 0 & 0 & 1 & 0 \end{bmatrix}$ |
| Ketol-acid reductoisomerase Phosphoglycerate dehydrogenase | 1 1 1 1 1 |
| L-Lactate dehydrogenase (cytochrome) | |
| D-Lactate dehydrogenase (cytochrome) | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| (S)-2-Hydroxy-acid oxidase Xanthine oxidase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Choline dehydrogenase | |
| Glucose dehydrogenase (acceptor) | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| Glycerol-3-phosphate dehydrogenase | 1 1 1 1 1 1 |
| Ubiquinolcytochrome-c reductase L-Ascorbate oxidase | |
| L-Ascorbate peroxidase | 0 0 0 0 |
| Catalase | 1 1 1 1 |
| Peroxidase Iodide peroxidase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Glutathione peroxidase | 1 1 1 1 |
| Tryptophan 2,3-dioxygenase | 1 1 1 0 0 |
| Cysteine dioxygenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 4-Hydroxyphenylpyruvate dioxygenase Arachidonate 12-lipoxygenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Arachidonate 15-lipoxygenase | 1 0 0 0 0 |
| Arachidonate 5-lipoxygenase | 1 0 0 0 |
| Indoleamine-pyrrole 2,3-dioxygenase Homogentisate 1,2-dioxygenase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| 3-Hydroxyanthranilate 3,4-dioxygenase | 1 0 1 1 0 |
| myo-Inositol oxygenase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| gamma-Butyrobetaine dioxygenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Procollagen-proline dioxygenase Procollagen-lysine 5-dioxygenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Trimethyllysine dioxygenase | 1 0 0 0 |
| Naringenin 3-dioxygenase | 0 1 0 0 1 |
| trans-Cinnamate 4-monooxygenase | 0 0 0 0 0 |
| Cholestanetriol 26-monooxygenase Cholesterol 7alpha-monooxygenase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| Flavonoid 3'-monooxygenase | |

| 169 | L-Pipecolate oxidase | 1 1 0 0 | 1 0 0 | |
|-----|---|---|---|--|
| | Sarcosine dehydrogenase | $ \begin{array}{ccccccccccccccccccccccccccccccccc$ | 0 0 1 | |
| | Dimethylglycine dehydrogenase | 1 1 0 | 0 0 1 | |
| | NAD(P)+ transhydrogenase (AB-specific) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccc} 0 & 0 & 1 \\ 1 & 1 & 1 \end{array}$ | |
| | NADH dehydrogenase (ubiquinone) NAD(P)H dehydrogenase (quinone) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| | Dihydropteridine reductase | 1 1 1 1 | 1 0 1 | |
| | Nitrate reductase (NADH) | 1 <u>1</u> 1 <u>1</u> | <u>1 1</u> 1 . | |
| | GMP reductase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 0 0 1 | |
| | Urate oxidase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccc} 1 & 1 & 1 \\ \hline 0 & 1 & 1 \end{array}$ | |
| | Ferredoxinnitrite reductase Sulfite reductase (NADPH) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 0 1 | |
| | Dihydrolipoamide dehydrogenase | 1 1 1 | i i i | |
| | Glutathione-disulfide reductase | 1 1 1 1_ | 1 1 1 | |
| | Thioredoxin-disulfide reductase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| | Sulfite oxidase Phosphoadenylyl-sulfate reductase (thioredoxin) | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $egin{array}{cccc} 0 & 0 & 1 \\ \hline 1 & 0 & 1 \\ \end{array}$ | |
| | Sulfite reductase (ferredoxin) | | 0 1 1 | |
| | Cytochrome-c oxidase | 1 1 1 1 | 1 1 1 | |
| | Nicotinamide N-methyltransferase | 1 0 1 0 | 0 0 0 | |
| | Homocysteine S-methyltransferase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccc} 1 & 1 & 1 \\ \hline 0 & 1 & 1 \end{array}$ | |
| | Caffeovl-CoA O-methyltransferase Uroporphyrin-III C-methyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 | |
| | Magnesium-protoporphyrin O-methyltransferase | 0 0 0 0 | 0 1 1 | |
| | 5-Methyltetrahydrofolatehomocysteine S-methyltransferase | 1 0 1 0 | 0 0 1 | |
| | 5-Methyltetrahydropteroyltriglutamatehomocysteine | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{ccc} 1 & 1 & 1 \\ 1 & 0 & 1 \end{array}$ | |
| | Phosphatidylethanolamine N-methyltransferase Guanidinoacetate N-methyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| | Glycine N-methyltransferase | 1 1 0 0 | 0 0 0 | |
| 198 | Phenylethanolamine N-methyltransferase | 1 | 0 0 | |
| 199 | DNA (cytosine-5-)-methyltransferase | 1 1 0 | $\begin{bmatrix} 0 & 1 \\ 0 & 0 \end{bmatrix} = \begin{bmatrix} 0 \\ 0 \end{bmatrix}$ | |
| | Acetylserotonin N-methyltransferase Histone-lysine N-methyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $egin{array}{cccc} 0 & 0 & 0 \\ 1 & 1 & 0 \\ \end{array}$ | |
| | Thymidylate synthase | iiii | i i i | |
| | Amine N-methyltransferase | 1 0 1 0 | 0 0 0 | |
| | Betainehomocysteine S-methyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 0 0 1 | |
| | Catechol O-methyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | |
| | Ouercetin 3-O-methyltransferase Histamine N-methyltransferase | 1 0 0 0 | 0 0 | |
| | Glycine hydroxymethyltransferase | i i i i | 1 1 1 | |
| 209 | Aminomethyltransferase | 1 1 1 1 | 1 1 1 | |
| | 3-Methyl-2-oxobutanoate hydroxymethyltransferase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 1 1 1 | |
| | Phosphoribosylglycinamide formyltransferase | 1 1 1 1 | 1 1 1 | |
| | Phosphoribosylaminoimidazolecarboxamide formyltransferase Glutamate formiminotransferase | 1 0 0 0 | | |
| | Methionyl-tRNA formyltransferase | 1 1 0 1 | 1 1 1 | |
| | Aspartate carbamoyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 | |
| | Ornithine carbamovltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | |
| | Glycine amidinotransferase Transketolase | 1 1 1 1 | 1 1 1 | |
| | Transaldolase | iiii | îîîî | |
| | Acetolactate synthase | 1 <u>1</u> 1 | 1 1 1 | |
| | Amino-acid N-acetyltransferase | 1 0 0 1 | 1 1 1 | |
| 222 | Dihydrolipoamide S-acetyltransferase Acyl-[acyl-carrier-protein]-UDP-N-acetylglucosamine O-acyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| | Glycerol-3-phosphate O-acyltransferase | 1 1 1 0 | | |
| 225 | Acetyl-CoA C-acyltransferase | i <u>i i i 1</u> | 0 1 1 | |
| 226 | Diacylglycerol O-acyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 0 0 0 | |
| | Carnitine O-palmitovltransferase | 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 | $egin{pmatrix} 0 & 0 & 0 \\ \hline 1 & 0 & 0 \end{bmatrix}$ | |
| | Sterol O-acyltransferase Glycine C-acetyltransferase | | $\frac{1}{0}$ 0 $\frac{1}{1}$ | |
| | Serine O-acetyltransferase | $egin{bmatrix} 0 & 0 & 0 & 1 \ 0 & 0 & 0 & 1 \end{bmatrix}$ | 1 <u>1</u> 1 | |
| 231 | Homoserine O-acetyltransferase | | 1 0 1 | |
| | Glutamate N-acetyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 1 0 1 | |
| | 5-Aminolevulinate synthase [Acyl-carrier-protein] S-acetyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 0 0 | |
| | [Acyl-carrier-protein] S-malonyltransferase | i i i | i i i i | |
| 236 | Glucosamine-phosphate N-acetyltransferase | 0 1 1 1 | 1 1 1 | |
| | 3-Oxoacyl-[acyl-carrier-protein] synthase | 1 1 1 1 | 1 1 1 | |
| 238 | Serine C-palmitoyltransferase 1-Acylglycerol-3-phosphate O-acyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 | |
| | Diamine N-acetyltransferase | | i i i | |
| 241 | Choline O-acetyltransferase | 1 1 1 0 | 0 0 0 | |
| | Dihydrolipoamide S-succinyltransferase | 1 1 1 | $\frac{1}{0}$ | |
| | Glycine N-choloyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{pmatrix} 0 & 0 & 0 \\ 0 & 0 & 1 \end{pmatrix}$ | |
| | Carnitine O-acetyltransferase Naringenin-chalcone synthase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 0 1 1 | |
| | Fatty-acid synthase | 0 1 1 0 | $0 \qquad 0 \qquad 1$ | |
| 247 | Fatty-acyl-CoA synthase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $egin{array}{cccc} 1 & 0 & 0 \\ 1 & 0 & 0 \end{array}$ | |
| | Aralkylamine N-acetyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | | |
| | Acetyl-CoA C-acetyltransferase gamma-Glutamyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | |
| | Citrate (Si)-synthase | | i i i | |
| 252 | Hydroxymethylglutaryl-CoA synthase | $\underline{\hat{1}}$ $\underline{\hat{0}}$ $\underline{1}$ $\underline{1}$ | 1 1 1 | |
| | 2-isopropylmalate synthase | $\begin{bmatrix} 0 & 0 & 0 & 1 \\ 0 & 0 & 0 & 1 \end{bmatrix}$ | 1 1 | |
| 254 | Homocitrate synthase | 0 0 0 | 1 0 1 | |
| | | | | |

| 341 4-Aminobutyrate transaminase | 1 1 1 | 1 1 0 1 |
|--|---|---|
| 342 Alanine transaminase | 1 1 1 | 1 1 1 0 |
| 343 Branched-chain-amino-acid transaminase 344 Alanineglyoxylate transaminase | 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 345 Serineglyoxylate transaminase | $\hat{0}$ $\hat{0}$ $\hat{0}$ | 0 0 1 1 |
| 346 Tyrosine transaminase | $\begin{array}{cccc} 1 & 1 & 1 \\ 1 & 1 & 1 \end{array}$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 347 Serine-pyruvate transaminase 348 Phosphoserine transaminase | 1 1 1 | 1 1 1 1 |
| 349 Adenosylmethionine8-amino-7-oxononanoate transaminase | 0 0 0 | 1 0 1 1 |
| 350 Histidinol-phosphate transaminase 351 Hexokinase | $\begin{array}{c cccc} 0 & 0 & 0 \\ \hline 1 & 1 & 1 \end{array}$ | 1 1 1 1 |
| 352 6-Phosphofructo-2-kinase | i i i | <u>i i</u> i 0 |
| 353 Diacylglycerol kinase | 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 354 Dolichol kinase 355 6-Phosphofructokinase | 1 1 0 | 1 0 1 0 |
| 356 Deoxyguanosine kinase | $\hat{1}$ $\hat{0}$ $\hat{0}$ | 0 0 0 1 |
| 357 Gluconokinase 358 1D-myo-Inositol-triphosphate 3-kinase | $\begin{array}{c cccc} 0 & 0 & 1 \\ \hline 1 & 1 & 1 \end{array}$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 359 1-Phosphatidylinositol 3-kinase | i i i | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 360 Ribokinase | 1 1 1 | 1 1 1 1 |
| 361 Xylulokinase 362 Phosphoribulokinase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 363 Glucokinase | 0 0 0 | 1 0 0 1 |
| 364 Adenosine kinase | 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 365 Thymidine kinase 366 NAD+ kinase | 1 1 1 | 1 1 1 |
| 367 Dephospho-CoA kinase | 1 1 1 | 1 1 1 1 |
| 368 Adenylylsulfate kinase 369 Riboflavin kinase | 1 1 1 | 1 1 1 1 |
| 370 Glycerone kinase | $\hat{1}$ $\hat{0}$ $\hat{1}$ | <u>1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 </u> |
| 371 Ketohexokinase | 1 1 0 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 372 Glycerol kinase 373 Choline kinase | 1 1 1 | |
| 374 Pantothenate kinase | 1 1 1 | 1 1 1 1 |
| 375 Pyridoxal kinase 376 Mevalonate kinase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 1 1 1 |
| 377 Homoserine kinase | 0 0 0 | <u>1 1</u> 1 1 |
| 378 Fructokinase 379 Pyruvate kinase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 380 Uridine kinase | <u>i i i</u> | iiii |
| 381 Hydroxyethylthiazole kinase | 0 0 0 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 382 N-Acetylglucosamine kinase 383 Galactokinase | 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 384 N-Acylmannosamine kinase | 1 0 0 | 0 0 0 |
| 385 1-Phosphatidylinositol 4-kinase 386 1-Phosphatidylinositol-4-phosphate kinase | 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 387 Shikimate kinase | 0 0 0 | <u>i i</u> i i |
| 388 Deoxycitidine kinase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ |
| 389 Ethanolamine kinase 390 Pyrophosphatefructose-6-phosphate 1-phosphotransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 391 Glutamate 5-kinase | 1 0 1 | 1 1 1 |
| 392 Phosphoglycerate kinase 393 Aspartate kinase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | 1 1 1 1 1 1 |
| 394 Acetylglutamate kinase | 0 0 0 | 1 1 1 1 |
| 395 Creatine kinase 396 Arginine kinase | $\begin{array}{c ccccccccccccccccccccccccccccccccccc$ | $egin{array}{ccccc} 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 1 \end{array}$ |
| 397 Nucleoside-triphosphateadenylate kinase | 1 1 0 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 398 Cytidylate kinase | 1 1 1 | 1 1 1 1 |
| 399 Phosphomevalonate kinase 400 Adenylate kinase | $\begin{array}{cccc} 1 & 1 & 0 \\ 1 & 1 & 1 \end{array}$ | 1 1 1 1 1 1 1 |
| 401 Nucleoside-diphosphate kinase | 1 1 1 | 1 1 1 1 |
| 402 Phosphomethylpyrimidine kinase 403 Guanylate kinase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 1 |
| 404 dTMP kinase | iii | i i i i |
| 405 Ribose-phosphate pyrophosphokinase | 1 1 1 | 1 1 1 1 1 1 |
| 406 Thiamin pyrophosphokinase 407 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 1 |
| 408 GTP pyrophosphokinase | 0 1 1 | 0 0 1 1 |
| 409 Nicotinamide-nucleotide adenylyltransferase 410 UTPhexose-1-phosphate uridylyltransferase | 1 1 1 | 1 1 1 1 1 1 1 |
| 411 UDPglucosehexose-1-phosphate uridylyltransferase | 1 0 0 | 0 0 0 0 |
| 412 Mannose-1-phosphate guanylyltransferase | $\begin{array}{c cccc} & 0 & 0 & 1 \\ \hline & 1 & 1 & 1 \end{array}$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 413 Ethanolamine-phosphate cytidylyltransferase 414 Choline-phosphate cytidylyltransferase | 1 1 1 | |
| 415 FMN adenylyltransferase | 1 1 1 | 1 1 1 1 |
| 416 Mannose-1-phosphate guanylyltransferase (GDP) 417 UDP-N-acetylglucosamine pyrophosphorylase | 1 1 1 | $egin{array}{c cccc} 0 & 0 & 1 & 1 \\ \hline 1 & 1 & 1 & 1 \end{array}$ |
| 418 Glucose-1-phosphate adenylyltransferase | 0 0 0 | 0 0 1 1 |
| 419 Fucose-1-phosphate guanylyltransferase | $\begin{bmatrix} 1 & 0 & 0 \\ 0 & 0 & 0 \end{bmatrix}$ | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 420 3-Deoxy-manno-octulosonate cytidylyltransferase 421 Sulfate adenylyltransferase | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | 1 1 1 1 |
| 422 Phosphatidate cytidylyltransferase | 1 1 1 | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 423 N-Acylneuraminate cytidylyltransferase 424 Sulfate adenylyltransferase (ADP) | $\begin{array}{cccccccccccccccccccccccccccccccccccc$ | $egin{array}{cccccccccccccccccccccccccccccccccccc$ |
| 425 ATP adenylyltransferase | 0 = 0 = 0 | 1 0 0 0 |
| 426 DNA-directed RNA polymerase | 1 1 1 | 1 1 1 1 |
| | | |





Supplementary table 2. List of enzymatic reactions included in the 104 metabolic networks

Metabolic network

Enzyme involved with the ER

Urea cycle and metabolism of amino groups

ER

- 115 N-Acetyl-gamma-glutamyl-phosphate reductase
- 116 Glutamate-5-semialdehyde dehydrogenase
- 148 Glutamate dehydrogenase (NAD(P)+)
- 161 Pyrroline-5-carboxylate reductase
- 170 Sarcosine dehydrogenase
- 196 Guanidinoacetate N-methyltransferase
- 216 Ornithine carbamoyltransferase
- 217 Glycine amidinotransferase
- 221 Amino-acid N-acetyltransferase
- 232 Glutamate N-acetyltransferase
- 321 Spermidine synthase
- 325 Spermine synthase
- 338 Acetylornithine transaminase
- 339 Ornithine-oxo-acid transaminase
- 394 Acetylglutamate kinase
- 391 Glutamate 5-kinase
- 395 Creatine kinase
- 544 Urease
- 535 Aminoacylase
- 537 Acetylornithine deacetylase
- 545 Allophanate hydrolase
- 551 Arginase
- 591 Ornithine decarboxylase
- 653 Argininosuccinate lyase
- 742 Argininosuccinate synthase
- 743 Urea carboxylase
- 738 Carbamoyl-phosphate synthase (ammonia)

Glutamate metabolism

- 108 Succinate-semialdehyde dehydrogenase (NAD(P)+)
- 111 Succinate-semialdehyde dehydrogenase
- 147 Glutamate dehydrogenase
- 148 Glutamate dehydrogenase (NAD(P)+)
- 149 Glutamate dehydrogenase (NADP+)
- 146 Glutamate synthase (NADPH)
- 159 1-Pyrroline-5-carboxylate dehydrogenase
- 182 Glutathione-disulfide reductase
- 236 Glucosamine-phosphate N-acetyltransferase
- 302 Amidophosphoribosyltransferase
- 337 Aspartate transaminase
- 342 Alanine transaminase
- 340 Glutamine-fructose-6-phosphate transaminase (isomerizing)
- 341 4-Aminobutyrate transaminase
- 382 N-Acetylglucosamine kinase
- 538 Glutaminase
- 590 Glutamate decarboxylase
- 592 Arginine decarboxylase
- 707 Glutamate-tRNA ligase
- 708 Glutamine-tRNA ligase727 Glutamate-ammonia ligase
- 730 Glutamate-cysteine ligase
- 731 Glutathione synthase
- 738 Carbamoyl-phosphate synthase (ammonia)
- 744 NAD+ synthase (glutamine-hydrolysing)
- 745 GMP synthase (glutamine-hydrolysing)
- 748 Carbamoyl-phosphate synthase (glutamine-hydrolysing)

Alanine and aspartate metabolism

- 150 D-Aspartate oxidase
- 151 L-Aspartate oxidase
- 215 Aspartate carbamoyltransferase

- 194 5-Methyltetrahydropteroyltriglutamate-homocysteine
- 199 DNA (cytosine-5-)-methyltransferase
- 214 Methionyl-tRNA formyltransferase
- 231 Homoserine O-acetyltransferase
- 335 Methionine adenosyltransferase
- 331 Cystathionine gamma-synthase
- 332 O-acetylhomoserine aminocarboxypropyltransferase
- 526 Adenosylhomocysteinase
- 628 Cystathionine beta-synthase
- 656 Cystathionine gamma-lyase
- 660 Cystathionine beta-lyase
- 701 Methionine-tRNA ligase

Cysteine metabolism

- 24 L-Lactate dehydrogenase
- 65 Cysteine dioxygenase
- 230 Serine O-acetyltransferase
- 330 Cysteine synthase
- 331 Cystathionine gamma-synthase
- 332 O-acetylhomoserine aminocarboxypropyltransferase
- 337 Aspartate transaminase
- 439 3-Mercaptopyruvate sulfurtransferase
- 647 L-serine ammonia-lyase
- 656 Cystathionine gamma-lyase
- 660 Cystathionine beta-lyase
- 706 Cysteine-tRNA ligase

Valine, leucine and isoleucine degradation

- 28 3-Hydroxyisobutyrate dehydrogenase
- 30 3-Hydroxyacyl-CoA dehydrogenase
- 113 Aldehyde dehydrogenase (NAD+)
- 112 Methylmalonate-semialdehyde dehydrogenase (acylating)
- 120 Aldehyde oxidase
- 123 3-Methyl-2-oxobutanoate dehydrogenase (lipoamide)
- 141 Butyryl-CoA dehydrogenase
- 142 Acyl-CoA dehydrogenase
- 139 Isovaleryl-CoA dehydrogenase
- 225 Acetyl-CoA C-acyltransferase
- 252 Hydroxymethylglutaryl-CoA synthase
- 343 Branched-chain-amino-acid transaminase
- 446 3-Oxoacid CoA-transferase
- 618 Hydroxymethylglutaryl-CoA lyase
- 624 Enoyl-CoA hydratase
- 692 Methylmalonyl-CoA mutase
- 750 Propionyl-CoA carboxylase
- 751 Methylcrotonoyl-CoA carboxylase

Valine, leucine and isoleucine biosynthesis

- 47 3-Isopropylmalate dehydrogenase
- 48 Ketol-acid reductoisomerase
- 121 Pyruvate dehydrogenase (lipoamide)
- 220 Acetolactate synthase
- 253 2-isopropylmalate synthase
- 343 Branched-chain-amino-acid transaminase
- 641 Dihydroxy-acid dehydratase
- 631 3-Isopropylmalate dehydratase
- 715 Leucine-tRNA ligase
- 716 Isoleucine-tRNA ligase
- 719 Valine-tRNA ligase

Lysine biosynthesis

- 26 Homoserine dehydrogenase
- 106 Aspartate-semialdehyde dehydrogenase
- 114 L-Aminoadipate-semialdehyde dehydrogenase
- 129 Dihydrodipicolinate reductase
- 165 Saccharopine dehydrogenase (NAD+, L-lysine forming)

- 153 Amine oxidase (flavin-containing)
- 155 Amine oxidase (copper-containing)
- 207 Histamine N-methyltransferase
- 213 Glutamate formiminotransferase
- 303 ATP phosphoribosyltransferase
- 350 Histidinol-phosphate transaminase
- 464 Histidinol-phosphatase
- 536 Aspartoacylase
- 559 Phosphoribosyl-AMP cyclohydrolase
- 579 Phosphoribosyl-ATP pyrophosphatase
- 594 Histidine decarboxylase
- 596 Aromatic-L-amino-acid decarboxylase
- 625 Imidazoleglycerol-phosphate dehydratase
- 635 Urocanate hydratase
- 649 Histidine ammonia-lyase
- 674 phosphoribosylformiminoaminophosphoribosylimidazolecarboxamide isomerase
- 712 Histidine-tRNA ligase

Tyrosine metabolism

- 1 Alcohol dehydrogenase
- 118 Aldehyde dehydrogenase (NAD(P)+)
- 108 Succinate-semialdehyde dehydrogenase (NAD(P)+)
- 120 Aldehyde oxidase
- 153 Amine oxidase (flavin-containing)
- 155 Amine oxidase (copper-containing)
- 62 Iodide peroxidase
- 71 Homogentisate 1,2-dioxygenase
- 66 4-Hydroxyphenylpyruvate dioxygenase
- 91 Tyrosine 3-monooxygenase
- 93 Dopamine beta-monooxygenase
- 94 Monophenol monooxygenase
- 205 Catechol O-methyltransferase
- 198 Phenylethanolamine N-methyltransferase
- 337 Aspartate transaminase
- 346 Tyrosine transaminase
- 350 Histidinol-phosphate transaminase
- 587 Fumarylacetoacetase
- 596 Aromatic-L-amino-acid decarboxylase
- 651 Phenylalanine ammonia-lyase
- 672 Maleylacetoacetate isomerase

Phenylalanine metabolism

- 118 Aldehyde dehydrogenase (NAD(P)+)
- 153 Amine oxidase (flavin-containing)
- 155 Amine oxidase (copper-containing)
- 61 Peroxidase
- 66 4-Hydroxyphenylpyruvate dioxygenase
- 79 trans-Cinnamate 4-monooxygenase
- 337 Aspartate transaminase
- 346 Tyrosine transaminase
- 350 Histidinol-phosphate transaminase
- 542 Amidase
- 596 Aromatic-L-amino-acid decarboxylase
- 651 Phenylalanine ammonia-lyase

Tryptophan metabolism

- 30 3-Hydroxyacyl-CoA dehydrogenase
- 113 Aldehyde dehydrogenase (NAD+)
- 120 Aldehyde oxidase
- 122 Oxoglutarate dehydrogenase (lipoamide)
- 145 Glutaryl-CoA dehydrogenase
- 153 Amine oxidase (flavin-containing)
- 155 Amine oxidase (copper-containing)
- 60 Catalase
- 72 3-Hydroxyanthranilate 3,4-dioxygenase

- 145 Glutaryl-CoA dehydrogenase
- 249 Acetyl-CoA C-acetyltransferase
- 542 Amidase
- 567 Nitrilase
- 582 Acylphosphatase
- 624 Enoyl-CoA hydratase

Styrene degradation

- 71 Homogentisate 1,2-dioxygenase
- 542 Amidase
- 587 Fumarylacetoacetase
- 672 Maleylacetoacetate isomerase

Atrazine degradation

- 544 Urease
- 545 Allophanate hydrolase

Caprolactam degradation

15 Alcohol dehydrogenase(NADP+)

Streptomycin biosynthesis

- 466 myo-Inositol-1(or 4)-monophosphatase
- 687 Phosphoglucomutase
- 698 myo-Inositol-1-phosphate synthase

Erythromycin biosynthesis

- 351 Hexokinase
- 363 Glucokinase
- 633 dTDPglucose 4,6-dehydratase
- 687 Phosphoglucomutase

Terpenoid biosynthesis

- 100 Squalene monooxygenase
- 318 Dimethylallyltranstransferase
- 319 Geranyltranstransferase
- 324 Farnesyl-diphosphate farnesyltransferase
- 327 Farnesyltranstransferase
- 655 Strictosidine synthase
- 680 Isopentenyl-diphosphate delta-isomerase

Flavonoids, stilbene and lignin biosynthesis

- 14 Cinnamyl-alcohol dehydrogenase
- 19 Dihydrokaempferol 4-reductase
- 61 Peroxidase
- 78 Naringenin 3-dioxygenase
- 79 trans-Cinnamate 4-monooxygenase
- 82 Flavonoid 3'-monooxygenase
- 94 Monophenol monooxygenase
- 206 Quercetin 3-O-methyltransferase
- 190 Caffeoyl-CoA O-methyltransferase
- 245 Naringenin-chalcone synthase
- 297 Flavonol 3-O-glucosyltransferase
- 503 beta-Glucosidase
- 699 Chalcone isomerase
- 721 4-Coumarate-CoA ligase

Alkaloid biosynthesis I

- 94 Monophenol monooxygenase
- 337 Aspartate transaminase
- 346 Tyrosine transaminase
- 596 Aromatic-L-amino-acid decarboxylase

Alkaloid biosynthesis II

- 155 Amine oxidase (copper-containing)
- 591 Ornithine decarboxylase

- 610 Fructose-bisphosphate aldolase
- 666 Ribulose-phosphate 3-epimerase
- 676 Ribose-5-phosphate epimerase
- 678 Glucose-6-phosphate isomerase
- 687 Phosphoglucomutase

Inositol metabolism

- 112 Methylmalonate-semialdehyde dehydrogenase (acylating)
- 673 Triose-phosphate isomerase

Pentose and glucuronate interconversions

- 15 Alcohol dehydrogenase(NADP+)
- 18 Aldehyde reductase
- 20 UDPglucose 6-dehydrogenase
- 277 Glucuronosyltransferase
- 361 Xylulokinase
- 429 UTP-glucose-1-phosphate uridylyltransferase
- 447 Pectinesterase
- 499 Polygalacturonase
- 666 Ribulose-phosphate 3-epimerase

Fructose and mannose metabolism

- 4 L-Iditol 2-dehydrogenase
- 18 Aldehyde reductase
- 25 GDP-L-fucose synthase
- 351 Hexokinase
- 371 Ketohexokinase
- 378 Fructokinase
- 355 6-Phosphofructokinase
- 390 Pyrophosphate-fructose-6-phosphate 1-phosphotransferase
- 352 6-Phosphofructo-2-kinase
- 412 Mannose-1-phosphate guanylyltransferase
- 416 Mannose-1-phosphate guanylyltransferase (GDP)
- 419 Fucose-1-phosphate guanylyltransferase
- 461 Fructose-bisphosphatase
- 471 Fructose-2,6-bisphosphate 2-phosphatase
- 610 Fructose-bisphosphate aldolase
- 634 GDPmannose 4,6-dehydratase
- 673 Triose-phosphate isomerase
- 677 Mannose-6-phosphate isomerase
- 690 Phosphomannomutase

Galactose metabolism

- 18 Aldehyde reductase
- 280 Lactose synthase
- 351 Hexokinase
- 363 Glucokinase
- 383 Galactokinase
- 355 6-Phosphofructokinase
- 429 UTP-glucose-1-phosphate uridylyltransferase
- 410 UTP-hexose-1-phosphate uridylyltransferase
- $411\ UDP glucose-hexose-1-phosphate\ uridylyl transferase$
- 477 Glucose-6-phosphatase
- 502 alpha-Glucosidase
- 504 alpha-Galactosidase
- 505 beta-Galactosidase
- 508 beta-Fructofuranosidase
- 494 Lactase
- 669 UDPglucose 4-epimerase
- 687 Phosphoglucomutase

Ascorbate and aldarate metabolism

- 113 Aldehyde dehydrogenase (NAD+)
- 132 Galactonolactone dehydrogenase
- 58 L-Ascorbate oxidase

- 725 Succinate-CoA ligase (GDP-forming)
- 726 Succinate-CoA ligase (ADP-forming)
- 722 Acetate-CoA ligase (ADP-forming)
- 750 Propionyl-CoA carboxylase

Butanoate metabolism

- 34 (R,R)-Butanediol dehydrogenase
- 27 3-Hydroxybutyrate dehydrogenase
- 30 3-Hydroxyacyl-CoA dehydrogenase
- 8 3-Hydroxybutyryl-CoA dehydrogenase
- 113 Aldehyde dehydrogenase (NAD+)
- 108 Succinate-semialdehyde dehydrogenase (NAD(P)+)
- 111 Succinate-semialdehyde dehydrogenase
- 121 Pyruvate dehydrogenase (lipoamide)
- 141 Butyryl-CoA dehydrogenase
- 220 Acetolactate synthase
- 249 Acetyl-CoA C-acetyltransferase
- 252 Hydroxymethylglutaryl-CoA synthase
- 341 4-Aminobutyrate transaminase
- 446 3-Oxoacid CoA-transferase
- 590 Glutamate decarboxylase
- 618 Hydroxymethylglutaryl-CoA lyase
- 624 Enoyl-CoA hydratase
- 723 Butyrate-CoA ligase

C5-Branched dibasic acid metabolism

- 220 Acetolactate synthase
- 726 Succinate-CoA ligase (ADP-forming)

Oxidative phosphorylation

- 138 Succinate dehydrogenase (ubiquinone)
- 173 NADH dehydrogenase (ubiquinone)
- 187 Cytochrome-c oxidase
- 57 Ubiquinol-cytochrome-c reductase
- 570 Inorganic pyrophosphatase
- 586 H+-exporting ATPase
- 584 H+/K+-exchanging ATPase

ATP synthesis

585 H+-transporting two-sector ATPase

Photosynthesis

- 104 Ferredoxin-NADP+ reductase
- 585 H+-transporting two-sector ATPase

Methane metabolism

- 105 Formaldehyde dehydrogenase (glutathione)
- 110 Formate dehydrogenase
- 60 Catalase
- 61 Peroxidase
- 208 Glycine hydroxymethyltransferase

Carbon fixation

- 31 Malate dehydrogenase
- 33 Malate dehydrogenase (decarboxylating)
- 35 Malate dehydrogenase (oxaloacetate-decarboxylating)(NADP+)
- 46 Malate dehydrogenase (NADP+)
- 218 Transketolase
- 337 Aspartate transaminase
- 342 Alanine transaminase
- 362 Phosphoribulokinase
- 379 Pyruvate kinase
- 392 Phosphoglycerate kinase
- 436 Pyruvate, orthophosphate dikinase
- 461 Fructose-bisphosphatase

- 234 [Acyl-carrier-protein] S-acetyltransferase
- 235 [Acyl-carrier-protein] S-malonyltransferase
- 237 3-Oxoacyl-[acyl-carrier-protein] synthase
- 246 Fatty-acid synthase
- 247 Fatty-acyl-CoA synthase
- 458 Oleoyl-[acyl-carrier-protein] hydrolase
- 638 3-Hydroxypalmitoyl-[acyl-carrier-protein] dehydratase
- 737 Biotin carboxylase

Fatty acid biosynthesis (path 2)

- 30 3-Hydroxyacyl-CoA dehydrogenase
- 249 Acetyl-CoA C-acetyltransferase
- 225 Acetyl-CoA C-acyltransferase
- 458 Oleoyl-[acyl-carrier-protein] hydrolase
- 624 Enoyl-CoA hydratase

Fatty acid metabolism

- 1 Alcohol dehydrogenase
- 30 3-Hydroxyacyl-CoA dehydrogenase
- 113 Aldehyde dehydrogenase (NAD+)
- 137 Acyl-CoA oxidase
- 141 Butyryl-CoA dehydrogenase
- 142 Acyl-CoA dehydrogenase
- 145 Glutaryl-CoA dehydrogenase
- 140 Long-chain-acyl-CoA dehydrogenase
- 86 Unspecific monooxygenase
- 87 Alkane 1-monooxygenase
- 249 Acetyl-CoA C-acetyltransferase
- 225 Acetyl-CoA C-acyltransferase
- 227 Carnitine O-palmitoyltransferase
- 624 Enoyl-CoA hydratase
- 682 Dodecenoyl-CoA delta-isomerase
- 724 Long-chain-fatty-acid-CoA ligase

Synthesis and degradation of ketone bodies

- 27 3-Hydroxybutyrate dehydrogenase
- 249 Acetyl-CoA C-acetyltransferase
- 252 Hydroxymethylglutaryl-CoA synthase
- 446 3-Oxoacid CoA-transferase
- 618 Hydroxymethylglutaryl-CoA lyase

Sterol biosynthesis

- 29 Hydroxymethylglutaryl-CoA reductase (NADPH)
- 127 7-Dehydrocholesterol reductase
- 134 Lathosterol oxidase
- 174 NAD(P)H dehydrogenase (quinone)
- 100 Squalene monooxygenase
- 98 Carotene 7,8-desaturase
- 318 Dimethylallyltranstransferase
- 319 Geranyltranstransferase
- 324 Farnesyl-diphosphate farnesyltransferase
- 327 Farnesyltranstransferase
- 376 Mevalonate kinase
- 399 Phosphomevalonate kinase
- 600 Diphosphomevalonate decarboxylase
- 680 Isopentenyl-diphosphate delta-isomerase
- 681 Cholestenol delta-isomerase
- 695 Lanosterol synthase
- 696 Cycloartenol synthase

Bile acid biosynthesis

- 1 Alcohol dehydrogenase
- 41 3alpha-Hydroxysteroid dehydrogenase (B-specific)
- 113 Aldehyde dehydrogenase (NAD+)
- 143 3-Oxo-5alpha-steroid 4-dehydrogenase

573 Nucleoside-triphosphatase

Riboflavin metabolism

- 13 5-Amino-6-(5-phosphoribosylamino)uracil reductase
- 94 Monophenol monooxygenase
- 336 Riboflavin synthase
- 369 Riboflavin kinase
- 415 FMN adenylyltransferase
- 465 Acid phosphatase
- 560 GTP cyclohydrolase II
- 561 Diaminohydroxyphosphoribosylaminopyrimidine deaminase
- 583 Nucleotide pyrophosphatase

Vitamin B6 metabolism

- 120 Aldehyde oxidase
- 154 Pyridoxamine-phosphate oxidase
- 348 Phosphoserine transaminase
- 375 Pyridoxal kinase
- 643 Threonine synthase

Nicotinate and nicotinamide metabolism

- 120 Aldehyde oxidase
- 172 NAD(P)+ transhydrogenase (AB-specific)
- 188 Nicotinamide N-methyltransferase
- 299 Purine-nucleoside phosphorylase
- 301 Nicotinate phosphoribosyltransferase
- 305 Nicotinate-nucleotide pyrophosphorylase (carboxylating)
- 366 NAD+ kinase
- 409 Nicotinamide-nucleotide adenylyltransferase
- 472 5'-Nucleotidase
- 525 NAD+ nucleosidase
- 583 Nucleotide pyrophosphatase
- 744 NAD+ synthase (glutamine-hydrolysing)

Pantothenate and CoA biosynthesis

- 48 Ketol-acid reductoisomerase
 - 9 2-Dehydropantoate 2-reductase
- 126 Dihydropyrimidine dehydrogenase (NADP+)
- 210 3-Methyl-2-oxobutanoate hydroxymethyltransferase
- 220 Acetolactate synthase
- 343 Branched-chain-amino-acid transaminase
- 367 Dephospho-CoA kinase
- 374 Pantothenate kinase
- 546 beta-Ureidopropionase
- 547 Dihydropyrimidinase
- 583 Nucleotide pyrophosphatase
- 641 Dihydroxy-acid dehydratase
- 728 Pantoate-beta-alanine ligase

Biotin metabolism

- 349 Adenosylmethionine-8-amino-7-oxononanoate transaminase
- 440 Biotin synthase
- 534 Biotinidase
- 735 Dethiobiotin synthase

Folate biosynthesis

- 7 Sepiapterin reductase
- 162 Dihydrofolate reductase
- 175 Dihydropteridine reductase
- 202 Thymidylate synthase
- 320 Dihydropteroate synthase
- 407 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase
- 460 Alkaline phosphatase
- 531 gamma-Glu-X carboxypeptidase
- 558 GTP cyclohydrolase I

- 678 Glucose-6-phosphate isomerase
- 687 Phosphoglucomutase

N-Glycans biosynthesis

- 287 Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase
- 292 Glycoprotein 6-alpha-L-fucosyltransferase
- 295 Dolichyl-phosphate beta-D-mannosyltransferase
- 258 alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
- 261 Dolichyl-phosphate beta-glucosyltransferase
- 262 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase
- 265 Glycolipid 2-alpha-mannosyltransferase
- 269 alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase
- 270 beta-1.4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase
- 271 alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase
- 275 alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase
- 312 beta-Galactoside alpha-2,6-sialyltransferase
- 354 Dolichol kinase
- 432 chitobiosylpyrophosphoryldolichol synthase
- 493 Mannosvl-oligosaccharide glucosidase
- 495 Mannosyl-oligosaccharide 1,2-alpha-mannosidase
- 496 Mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase

N-Glycan degradation

- 500 Exo-alpha-sialidase
- 505 beta-Galactosidase
- 506 alpha-Mannosidase
- 507 beta-Mannosidase
- 519 alpha-L-Fucosidase
- 520 beta-N-Acetylhexosaminidase
- 524 Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase
- 541 N4-(beta-N-Acetylglucosaminyl)-L-asparaginase

O-Glycans biosynthesis

- 289 Polypeptide N-acetylgalactosaminyltransferase
- 259 beta6-N-acetylglucosaminyltransferase
- 263 Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase
- 313 beta-Galactoside alpha-2,3-sialyltransferase
- 315 sialyltransferase

Aminosugars metabolism

- 236 Glucosamine-phosphate N-acetyltransferase
- 276 Chitin synthase
- 340 Glutamine-fructose-6-phosphate transaminase (isomerizing)
- 351 Hexokinase
- 382 N-Acetylglucosamine kinase
- 384 N-Acylmannosamine kinase
- 417 UDP-N-acetylglucosamine pyrophosphorylase
- 423 N-Acylneuraminate cytidylyltransferase
- 497 Chitinase
- 520 beta-N-Acetylhexosaminidase
- 540 N-Acetylglucosamine-6-phosphate deacetylase
- 543 Chitin deacetylase
- 568 Glucosamine-6-phosphate deaminase
- 671 N-Acylglucosamine 2-epimerase
- 668 UDP-N-acetylglucosamine 2-epimerase
- 687 Phosphoglucomutase
- 688 Phosphoacetylglucosamine mutase

Glycosaminoglycan degradation

- 488 N-Acetylgalactosamine-6-sulfatase
- 484 N-Acetylgalactosamine-4-sulfatase
- 485 Iduronate-2-sulfatase
- 486 N-Acetylglucosamine-6-sulfatase
- 505 beta-Galactosidase
- 511 beta-Glucuronidase

- 607 Phosphatidylserine decarboxylase
- 673 Triose-phosphate isomerase

Inositol phosphate metabolism

- 73 myo-Inositol oxygenase
- 385 1-Phosphatidylinositol 4-kinase
- 386 1-Phosphatidylinositol-4-phosphate kinase
- 358 1D-myo-Inositol-triphosphate 3-kinase
- 359 1-Phosphatidylinositol 3-kinase
- 466 myo-Inositol-1(or 4)-monophosphatase
- 473 Inositol-1,4,5-trisphosphate 5-phosphatase
- 474 Inositol-1,4-bisphosphate 1-phosphatase
- 475 Inositol-3,4-bisphosphate 4-phosphatase
- 478 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase
- 698 myo-Inositol-1-phosphate synthase

Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 03-4-10

279 Phosphatidylinositol N-acetylglucosaminyltransferase

Sphingophospholipid biosynthesis

- 430 Ethanolaminephosphotransferase
- 479 Sphingomyelin phosphodiesterase

Phospholipid degradation

- 452 Prophospholipase A2
- 455 Lisophospholipase
- 469 Phosphatidate phosphatase
- 481 Phospholipase D
- 482 Glycerophosphodiester phosphodiesterase

Prostaglandin and leukotriene metabolism

- 10 Carbonyl reductase (NADPH)
- 11 Prostaglandin-F synthase
- 12 Prostaglandin-E2 9-reductase
- 67 Arachidonate 12-lipoxygenase
- 68 Arachidonate 15-lipoxygenase
- 69 Arachidonate 5-lipoxygenase
- 83 Leukotriene-B4 20-monooxygenase
- 95 Prostaglandin-endoperoxide synthase
- 250 gamma-Glutamyltransferase
- 329 Leukotriene-C4 synthase
- 452 Prophospholipase A2
- 528 Leukotriene-A4 hydrolase
- 642 Hydroperoxide dehydratase
- 683 Prostaglandin-D synthase
- 684 Prostaglandin-I synthase
- 685 Thromboxane-A synthase

Sphingoglycolipid metabolism

- 238 Serine C-palmitoyltransferase
- 290 Ganglioside galactosyltransferase
- 294 Ceramide glucosyltransferase
- 442 Galactosylceramide sulfotransferase
- 483 Arylsulfatase
- 489 Cerebroside-sulfatase
- 500 Exo-alpha-sialidase
- 504 alpha-Galactosidase
- 505 beta-Galactosidase
- 515 Glucosylceramidase
- 539 Ceramidase
- 612 Sphinganine-1-phosphate aldolase

Blood group glycolipid biosynthesis - lact series

- 286 Fucosylglycoprotein 3-alpha-galactosyltransferase
- 288 Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase

- 250 gamma-Glutamyltransferase
- 335 Methionine adenosyltransferase
- 330 Cysteine synthase
- 331 Cystathionine gamma-synthase
- 368 Adenylylsulfate kinase
- 421 Sulfate adenylyltransferase
- 438 Selenide, water dikinase
- 526 Adenosylhomocysteinase
- 628 Cystathionine beta-synthase
- 656 Cystathionine gamma-lyase
- 660 Cystathionine beta-lyase
- 701 Methionine-tRNA ligase

Cyanoamino acid metabolism

- 208 Glycine hydroxymethyltransferase
- 250 gamma-Glutamyltransferase
- 503 beta-Glucosidase
- 532 Asparaginase
- 542 Amidase
- 567 Nitrilase

D-Glutamine and D-glutamate metabolism

- 148 Glutamate dehydrogenase (NAD(P)+)
- 538 Glutaminase

D-Arginine and D-ornithine metabolism

- 107 Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating)
- 152 D-Amino-acid oxidase

D-Alanine metabolism

664 Alanine racemase

Glutathione metabolism

- 37 Isocitrate dehydrogenase (NADP+)
- 40 Glucose-6-phosphate 1-dehydrogenase
- 182 Glutathione-disulfide reductase
- 63 Glutathione peroxidase
- 250 gamma-Glutamyltransferase
- 322 Glutathione transferase
- 529 Membrane alanyl aminopeptidase
- 550 5-Oxoprolinase (ATP-hydrolysing)
- 730 Glutamate-cysteine ligase
- 731 Glutathione synthase

Purine metabolism

- 16 Xanthine dehydrogenase
- 17 IMP dehydrogenase
- 53 Xanthine oxidase
- 177 GMP reductase
- 178 Urate oxidase
- 103 Ribonucleoside-diphosphate reductase
- 211 Phosphoribosylglycinamide formyltransferase
- ${\tt 212\ Phosphoribosylaminoimidazole carboxamide\ formyl transferase}$
- 299 Purine-nucleoside phosphorylase
- 308 Thymidine phosphorylase
- 309 Adenine phosphoribosyltransferase
- $310\ Hypoxanthine\ phosphoribosyltrans ferase$
- 302 Amidophosphoribosyltransferase
- 364 Adenosine kinase
- 368 Adenylylsulfate kinase
- 379 Pyruvate kinase
- 388 Deoxycitidine kinase
- 356 Deoxyguanosine kinase
- 400 Adenylate kinase
- 401 Nucleoside-diphosphate kinase

- 555 Cytosine deaminase
- 564 Cytidine deaminase
- 557 dCMP deaminase
- 580 Apyrase
- 581 Nucleoside-diphosphatase
- 574 Bis(5'-nucleosyl)-tetraphosphatase (asymmetrical)
- 575 Nucleoside-triphosphate pyrophosphatase
- 576 dUTP pyrophosphatase
- 595 Orotidine-5'-phosphate decarboxylase
- 639 Pseudouridylate synthase
- 739 CTP synthase
- 748 Carbamoyl-phosphate synthase (glutamine-hydrolysing)

Nucleotide sugars metabolism

- 20 UDPglucose 6-dehydrogenase
- 429 UTP-glucose-1-phosphate uridylyltransferase
- 410 UTP-hexose-1-phosphate uridylyltransferase
- 411 UDPglucose-hexose-1-phosphate uridylyltransferase
- 633 dTDPglucose 4,6-dehydratase
- 669 UDPglucose 4-epimerase
- 667 dTDP-4-dehydrorhamnose 3,5-epimerase

Supplementary results 1

I analyzed the difference of the metabolic networks between the 6 eukaryotes based on the existence of ERs in detail. In this study, I separated 751 ERs into 104 metabolic networks. As results, I discovered the following four patterns for explaining the difference of the metabolic networks between species. Therefore, I show the examples of these patterns in supplementary results 1.

Pattern 1: Conservation

In this pattern, the sets of ERs constructing the metabolic network are conserved between all the 6 eukaryotes examined. There are only three out of 104 metabolic networks, ATP synthesis, 1,2-Dichloroethane degradation, and phospholipid degradation. As an example, I show the metabolic network of the phospholipids degradation. In this network, a total of five ERs are found in all the 6 eukaryotes.

Pattern 2: Alternative conservation

In this pattern, the metabolic network is different between the 6 eukaryotes examined by the existence of the alternative pathway. Therefore, the difference of the sets of the ER affects the difference of the metabolic networks but not affects the capability of the metabolic networks between the 6 eukaryotes examined. In other words, the losses of ERs in either lineage were complemented by the alternative pathways by the different ERs. As examples, I show the metabolic networks of the glycolysis and the citrate cycle (TCA cycle).

Glycolysis

The sets of ERs for the glycolysis are different between the 6 eukaryotes, however, the metabolic pathways from D-glucose to pyruvate or acetyl-CoA are functional among them.

Citrate cycle (TCA cycle)

Even if the sets of ERs for the citrate cycle are different between the 6 eukaryotes, the degrading pathway of pyruvate is functional among them.

Pattern 3: ER losses

In this pattern, the extremely losses of ERs are found in the metabolic networks in the particular lineages. The deficiency of the metabolic networks by the losses of ERs correlates well with the acquirement of the products in these networks as nourishment. As examples, I show the metabolic networks of the valine, leucine and isoleucine biosynthesis and the phenylalanine, tyrosine and tryptophan biosynthesis.

Valine, leucine and isoleucine biosynthesis

The five losses of ERs in this network were observed in the animal lineage. This result suggests that this network may not be functional in the animal lineages and, in fact, is consistent with the acquirements of valine, leucine and isoleucine as the essential amino acids for the animals.

Phenylalanine, tyrosine and tryptophan biosynthesis

In the case of plant and yeasts lineages, loss of ER is complemented by the different


ERs constructing the alternative pathways. On the other hand, a total of 16 losses of ERs are found in the animal lineages. This result suggests that this network may not be functional in the animal lineages. In fact, phenylalanine and tryptophan are the essential amino acid for the animals and tyrosine is not an essential amino acid by the existence of ER90, phenylalanine 4-monooxygenase, in the animal lineages.

Pattern 4: ER gains

In this pattern, the extremely gains of ERs were found in the metabolic networks in the particular lineages. It is considered that the gains of ERs give the species the capability to make the novel products. In my thesis, I have already explained about the metabolic network of prostaglandin and leukotriene metabolism as the example of this pattern. As another example, I show the metabolic network of flavonoid, stilbene and lignin biosynthesis.

Flavonoid, stilbene and lignin biosynthesis

Six ERs are found only in A. thaliana in this study. This means that gains of these ERs occurred only in the plant lineage. Since flavonoids are the plant pigments and essential compounds for plant reproduction, the gains of ERs could have contributed to the establishment of the plant-specific system of the reproduction.



Phospholipid degradation


Square indicates the enzymatic reaction existing in the 6 eukaryotes examined and circle indicates the substance.

Species-ER matrix for the Phospholipid degradation

| | | | | | Specie | es | | |
|-----|---|------|-----|-----|--------|-----|-----|-----|
| ER | Enzymes involved with the ER | H SA | DME | CEL | SCE | SPO | ATH | OUT |
| 452 | Prophospholipase A2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 455 | Lisophospholipase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 469 | Phosphatidate phosphatase | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 481 | Phospholipase D | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 482 | Glycerophosphodiester phosphodiesterase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

List of substrates in the phospholipid degradation

- 1: 2-Acylglycero-3-phosphocholine
- 2: 1-Alkenyl-2-acyl-glycero-3-phosphocholine
- 3: 1-Alkenyl-glycero-3-phosphocholine
- 4: Glycero-3-phosphocholine
- 5: Choline
- 6: Clycero-3P
- 7: 1-Acylglycero-3-phosphocholine
- 8: Fatty acid
- 9: Lecithin
- 10: 1,2-Diacylglycero-3P
- 11: 1,2-Diacylglycerol



Square indicates the enzymatic reaction and circle indicates the substance. The color of each squares correspond to the status changes of genes encoding the protein that is involved with the ER. White: Exist in all the 6 eukaryotes. Black: Lost in the animal lineages. Grey: Lost in the all lineages except for the *S. cerevisiae*. Grey blue: Lost in the yeasts and *C. elegans* lineages. Orange: Lost in the *D. melanogaster* lineage. Dark green: Lost in the *S. cerevisiae* lineage. Green: Gain in the vertebrate and insect lineages. Yellow: Gain in the yeast and animal lineage. Number in the circles indicate the name of the substrates (See the next page).

| | | | | | Species | | | |
|-----|---|------|-----|-----|---------|-----|-----|-----|
| ER | Enzymes involved with the ER | H SA | DME | CEL | SCE | SPO | ATH | OUT |
| 1 | Alcohol dehydrogenase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 15 | Alcohol dehydrogenase(NADP+) | 1 | 0 | 1 | 1 | 1 | 1 | |
| 24 | L-Lactate dehydrogenase | 1 | 1 | 1 | 0 | 1 | 1 | |
| 107 | Glyceraldehyde-3-phosphate dehydrogenase (phosphorylating) | 1 | 1 | 1 | 1 | 1 | 1 | |
| 113 | Aldehyde dehydrogenase (NAD+) | 1 | 1 | 1 | 1 | 1 | 1 | 201 |
| 118 | Aldehyde dehydrogenase (NAD(P)+) | 1 | 1 | 1 | 1 | 1 | 0 | |
| 121 | Pyruvate dehydrogenase (lipoamide) | 1 | 1 | 1 | 1 | 1 | 1 | |
| 181 | Dihydrolipoamide dehydrogenase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 222 | Dihydrolipoamide S-acetyltransferase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 351 | Hexokinase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 355 | 6-Phosphofructokinase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 363 | Glucokinase | 0 | 0 | 0 | 1 | 0 | 0 | |
| 379 | Pyruvate kinase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 392 | Phosphoglycerate kinase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 461 | Fructose-bisphosphatase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 463 | Bisphosphoglycerate phosphatase | 1 | 1 | 0 | 0 | 0 | 1 | |
| 477 | Glucose-6-phosphatase | 1 | 1 | . 0 | 0 | 0 | 0 | |
| 582 | Acylphosphatase | 1 | 1 | 0 | 0 | 0 | 1 | |
| 589 | Pyruvate decarboxylase | 0 | 0 | 0 | 1 | 1 | 1 | |
| 610 | Fructose-bisphosphate aldolase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 623 | Phosphopyruvate hydratase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 670 | Aldose 1-epimerase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 673 | Triose-phosphate isomerase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 678 | Glucose-6-phosphate isomerase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 686 | Phosphoglycerate mutase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 687 | Phosphoglucomutase | 1 | 1 | 1 | 1 | 1 | 1 | |
| 689 | Bisphosphoglycerate mutase | 1 | 1 | 0 | 0 | 0 | 1 | |
| 720 | Acetate-CoA ligase | 1 | 1 | 1 | 1 | 0 | 1 | |

Substrates in Glycolysis

1: alpha-D-Glucose-6P 2: beta-D-Glucose-6P 3: beta-D-Fructose-6P


4: beta-D-Fructose-1,6P25: Glycraldehyde-3P 6: Glycerone-P

7: Glycerate-1,3P2 8: Glycerate-2,3P2 9: Glycerate-3P

10: Glycerate-2P 11: Phosphoenolpyruvate 12: 2-Hydroxy-ethyl-ThPP

13: Lipoamide 14: Dihydrolipoamide 15: 6-S-Acetyl-dihydrolipoamide

16: Acetaldehyde 17: Ethanol 18: Acetate



Citrate cycle (TCA cycle)


Square indicates the enzymatic reaction and circle indicates the substance. White: Exist in all the 6 eukaryotes. Black: Lost in the animals and *S. pombe* lineages. Grey: Lost in the plant and yeasts lineages. Dark Blue: Lost in the plant, yeasts and *D. melanogaster* lineages. Orange: Lost in the *A. thaliana*. Green: Lost in the *S.* cerevisiae lineage. Number in the circles indicate the name of the substrates (See the next page).

Species-ER matrix for the Citrate cycle (TCA cycle)

| | | | | | Specie | es | | |
|-----|---|------|-----|-----|--------|-----|-----|-----|
| ER | Enzymes involved with the ER | H SA | DME | CEL | SCE | SPO | ATH | OUT |
| 31 | Malate dehydrogenase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 36 | Isocitrate dehydrogenase (NAD+) | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 37 | Isocitrate dehydrogenase (NADP+) | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 122 | Oxoglutarate dehydrogenase (lipoamide) | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 138 | Succinate dehydrogenase (ubiquinone) | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 181 | Dihydrolipoamide dehydrogenase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 242 | Dihydrolipoamide S-succinyltransferase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 251 | Citrate (Si)-synthase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 255 | ATP citrate synthase | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| 599 | Phosphoenolpyruvate carboxykinase (GTP) | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| 605 | Phosphoenolpyruvate carboxykinase (ATP) | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| 619 | Citrate lyase | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| 626 | Fumarate hydratase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 630 | Aconitate hydratase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 725 | Succinate-CoA ligase (GDP-forming) | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 726 | Succinate-CoA ligase (ADP-forming) | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| 749 | Pyruvate carboxylase | 1 | 1 | 1 | 1 | 1 | 0 | 1 |

List of the substrates in the citrate cycle (TCA cycle)

| 1: Phosphoenol-pyruvate | 2: Oxaloacetate |
|------------------------------------|----------------------|
| 3: Citrate | 4: Acetate |
| 5: cis-Acetate | 6: Isocitrate |
| 7: Oxalosuccinate | 8: 2-Oxoglutarate |
| 9: 3-Carbosy-1-hyddroxypropyl-ThPP | 10: Lipoamide |
| 11: S-Succinyl-dihydrolipoamide | 12: Dihydrolipoamide |
| 13: Succinyl-CoA | 14: Succinate |
| 15: Fumarate | 16: (S)-Malate |




Valine, leucine and isoleucine biosynthesis
Square indicates the enzymatic reaction and circle indicates the substance. The color of each squares correspond to the status changes of genes encoding the protein that is involved with the ER. White: Exist in all the 6 eukaryotes. Black: Lost in the animal lineage. Grey: Lost in the animals and *S. pombe* lineage. Number in the circles indicate the name of the substrates (See the next page).

Species-ER matrix for the valine, leucine and isoleucine biosynthesis

| | | | | | Specie | es | | |
|-----|--|------|-----|-----|--------|-----|-----|-----|
| ER | Enzymes involved with the ER | H SA | DME | CEL | SCE | SPO | ATH | OUT |
| 47 | 3-Isopropylmalate dehydrogenase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 48 | Ketol-acid reductoisomerase | 0 | 0 | 0 | 1 | 0 | 1 | 1 |
| 121 | Pyruvate dehydrogenase (lipoamide) | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 220 | Acetolactate synthase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 253 | 2-isopropylmalate synthase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 343 | Branched-chain-amino-acid transaminase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 631 | 3-Isopropylmalate dehydratase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 641 | Dihydroxy-acid dehydratase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 715 | Leucine-tRNA ligase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 716 | Isoleucine-tRNA ligase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 719 | Valine-tRNA ligase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

List of the substrates in the valine, leucine and isoleucine biosynthesis

- 1: 2-Hydroxyethyl-ThPP
- 2: (S)-2-Aceto-2-hydroxybutanoate
- 3: (S)-2-Hydroxy-3-methyl-3-oxopentanoate
- 4: (R)-2,3-Dihydroxy-3-methylpentanoate
- 5: (R)-2-Oxo-3-methyl-pentanoate
- 6: (S)-2-Acetolactate
- 7: (R)-3-Hydroxy-3-methyl-2-oxobutanoate
- 8: (R)-2,3-Dihydrosy-3-methylbutanoate
- 9: 2-Oxoisovalerate
- 10: 2-Isopropylmalate
- 11: 2-Isopropylmaleate
- 12: 3-Isopropylmalate
- 13: 2-Oxo-4-methyl-3-carboxypentanoate
- 14: e-Methyl-w-oxopentanoate



Square indicates the enzymatic reaction and circle indicates the substance. Black: Lost in the animal lineage. White: Exist in all the 6 eukaryotes. Yellow: Lost in the *S. pombe* lineage. Blue: Lost in the plant and yeast lineages. Number in the circles indicate the name of the substrates (See the next page).

Species-ER matrix for the phenylalanine, tyrosine and tryptophan biosynthesis


| | | | | | Species | | | |
|-----|--|------|-----|-----|---------|-----|-----|-----|
| ER | Enzymes involved with the ER | H SA | DME | CEL | SCE | SPO | ATH | OUT |
| 22 | Shikimate 5-dehydrogenase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 90 | Phenylalanine 4-monooxygenase | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| 125 | Prephenate dehydrogenase (NADP+) | 0 | 0 | 0 | 1 | 1 | 1 | 0 |
| 304 | Anthranilate phosphoribosyltransferase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 323 | 3-Phosphoshikimate 1-carboxyvinyltransferase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 333 | 3-deoxy-7-phosphoheptulonate synthase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 337 | Aspartate transaminase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| | Tyrosine transaminase | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| 350 | Histidinol-phosphate transaminase | . 0 | 0 | 0 | 1 | • 1 | 1 | 1 |
| 387 | Shikimate kinase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 604 | Indole-3-glycerol-phosphate synthase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 616 | Anthranilate synthase | 0 | 0 | 0 | . 1 | 1 | 1 | 1 |
| 621 | 3-Dehydroquinate dehydratase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 623 | Phosphopyruvate hydratase | 1 | 1 | 1 | 1 | 1 | 1 | 1. |
| 627 | Tryptophan synthase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 636 | Prephenate dehydratase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 645 | 3-dehydroquinate synthase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 646 | Chorismate synthase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 675 | Phosphoribosylanthranilate isomerase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 693 | Chorismate mutase | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| 700 | Tyrosine-tRNA ligase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 711 | Phenylalanine-tRNA ligase | 1 | 1 | 1 | 1 | 1 | 1 | 1 |

List of the substrates in the phenylalanine, tyrosine and tryptophan biosynthesis

- 1: Phosphoenol-pyruvate and D-Erythrose-4-phosphate
- 2: 7P-2-Dehydro-3-deoxy-D-arabino-heptonate
- 3: 3-Dehydro-quinate

- 4: Protocatechuate
- 5: 3-Dehydro-shikimate 6: Shikimate
- 7: Shikimate-3-phosphate
- 8: 5-O-(1-Carboxyvinyl)-3-phosphoshikimate

- 9: Chorismate
- 10: Anthranilate
- 11: N-(5-Phospho-beta-D-ribosyl)-anthranilate
- 12: 1-(2-Carbosy-phenylamino)-1-deoxy-D-ribulose-5-phosphate
- 13: (3-Indolyl)-glycerol-phosphate 14: Indole 15: Prephenate
- 16: 4-Hydrosy-phenylpyruvate
- 17: Phenylpyruvate
- 18: Pretyrosine



Flavonoid, stilbene and lignin biosynthesis

Square indicates the enzymatic reaction and circle indicates the substance. The color of each squares correspond to the status changes of genes encoding the protein that is involved with the ER. White: Exist in all the 6 eukaryotes. Black: Lost in the animals and yeasts lineage. Dark grey: Lost in the *H. sapiens*, *D. melanogaster* and S. cerevisiae lineages. Pale grey: Lost in plant and yeasts lineages. Dark blue: Lost in the *H. sapiens*, *C. elegans* and *S. cerevisiae* lineages. Pale blue: Lost in the *H. sapiens* and *D. melanogaster* lineage. Purple: Lost in the *D. melanogaster* and yeasts lineages. Orange: Lost in the *S. pombe* lineage. Green: Gain in the *A. thaliana* lineage. "?" indicates that the enzyme corresponding to the ER is unknown in this study. Circle colored in the green indicates the Flavonoids. Number in the circles indicate the name of the substrates (See the next page).

Species-ER matrix for the flavonoids, stilbene and lignin biosynthesis

| | | | | | Specie | s | | |
|-----|----------------------------------|------|-----|-----|--------|-----|-----|-----|
| ER | Enzymes involved with the ER | H SA | DME | CEL | SCE | SPO | ATH | OUT |
| 14 | Cinnamyl-alcohol dehydrogenase | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 19 | Dihydrokaempferol 4-reductase | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| 61 | Peroxidase | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| 78 | Naringenin 3-dioxygenase | 0 | 1 | 0 | 0 | 1 | 1 | 0 |
| 79 | trans-Cinnamate 4-monooxygenase | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 82 | Flavonoid 3'-monooxygenase | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 94 | Monophenol monooxygenase | 1 | 1 | 1 | 0 | 0 | 0 | 1 |
| 190 | Caffeoyl-CoA O-methyltransferase | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| 206 | Quercetin 3-O-methyltransferase | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 245 | Naringenin-chalcone synthase | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| 297 | Flavonol 3-O-glucosyltransferase | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 503 | beta-Glucosidase | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| 699 | Chalcone isomerase | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| 721 | 4-Coumarate-CoA ligase | 1 | 1 | 1 | 1 | 0 | 1 | 0 |

List of the substrates in the flavonoid, stilbene and lignin biosynthesis

| 1: | Sinapoy | aldehyde |
|----|---------|----------|
|----|---------|----------|

3: Coniferyl aldehyde

5: 4-Hydroxy-cinnamyl alcohol

7: Ferulate

9: Caffeoyl-CoA

11: Cinnamoyl-CoA

13: trans-4-Hydroxy-cinnamate

15: Naringenin-chalcone

17: Eriodictyol

19: Dihydrokaempferol

21: 3-Methosyapigenin

23: Dihydroquercetin

25: Dihydromyricetin

27: Quercetin

29: 3-Methoxy-luteolin

2: Sinapoyl alcohol

4: Coniferyl alcohol

6: 4-Hydroxy-cinnamyl aldehyde

8: Feruloyl-CoA

10: trans-Caffeate

12: trans-Cinnamate

14: 4-Hydroxy-cinnamoyl-CoA

16: Naringenin

18: Pentahydroxy-flavanone

20: Kaempferol

22: cis-3,4-Leucopelargondin

24: Leucocyanidin

26: Leucodelphinidin

28: Quercetin-3-O-glucoside

The name of substrates in bold indicate the flavonoids.

Supplementary results 2

I evaluated the possibility of the emergence of ERs in particular lineage by conducting the homology search of the 58 protein sequences discovered in only one species examined to the non redundant protein database as of Jan. 7th 2004 in NCBI. After making the 58 phylogenetic trees using the matched sequences, I categorized each tree into the following four patterns named origination, duplication, diversification and false-positive.

Origination means that homologous sequence of the protein involved with the ER is found only in the ER-gained lineage. For example, ER207, histamine N-methyltransferase, was found in *H. sapiens* between the 6 eukaryotes examined and I concluded that the ER had gained in the vertebrate lineage after the separation from the *D. melanogaster*. As a result of the homology search, homologous sequences of the proteins involved in ER207 were found only in the vertebrate lineages. Therefore, I conclude that ER207 was gained in the vertebrate lineage.

Duplication means that the gained ER is caused by the gene duplication only in the ER-gained lineage. For example, ER96, steroid 21alpha-monooxygenase, was found only in *H. sapiens* in this study and I concluded that the ER had been gained in the vertebrate lineage after the separation from the *D. melanogaster*. From the topology of the phylogenetic tree, it was found that the gene involved in the ER generated by the gene duplication from the other ER, steroid 17alpha-monooxygenase. Therefore, I conclude that ER96 was gained in the vertebrate lineage by the gene duplication and neo-functionalization of the duplicated gene.


Diversifiation means that the new ER generates by the change of the

substrate-specificity of enzyme. For example, ER217, Glycine amidonotransferase, was found in *H. sapiens* in this study and I concluded that the ER had been gained in the vertebrate lineage after the separation from the *D. melanogaster*. As a result of the homology search, the sequences homologous to the enzyme involved in the ER were also found in bacterial lineages. However, the substrate-specificities of the enzymes were different between the vertebrate and the bacteria, glycine and inosamine-phosphate, respectively. Therefore, I conclude that ER217 was gained in the vertebrate lineage by the change of substrate-specificity of enzyme.

False-positive means that the timing of the ER gain may date back to the backward of my estimation. For example, ER671, N-acylglucosamine 2-epimearase, was found in *H. sapiens* in this study and I concluded that the ER had been gained in the vertebrate lineage after the separation from the *D. melanogaster*. However, as a result of the homology search, the homologous sequences of the enzyme involved in the ER were found in bacteria. Because the function of the genes discovered in bacteria were unknown, I could not decide when the ER generated. Therefore, it is conceivable that the generation of ER671 was older than my estimation. The false-positive result is caused by the limitation of the dataset that I used in this study. By the increase of the sequences in the database, the possibility to discover the homologous sequence of the targeted gene will also increase. This result suggests that the timing of ER gain may be changeable by the increase of the sequences examined.


Out of 58 ERs, 18 ERs (31%) were in the origination, 26 ERs (45%) were in the duplication, 8 ERs (14%) were in the diversification and 6 ERs (10%) were in the false-positive. These results suggest that the 10% of ER gains that I estimated was affected by the dataset of the sequences and may date back to the backward.

Pattern 1Histamine N-methyltransferase (ER207)




^{0.1 (}amino acid substitution per site)

Pattern 2 Steroid 21-monooxygenase (ER96)



Pattern 3 Glycine amidinotransferase (ER217)



Pattern 4 N-acylglucosamine 2-epimerase (ER671)

